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While antiretroviral therapy (ART) has extended the life expectancy of those infected with 
HIV, it is also associated with a number of metabolic complications, such as dysglycaemia, 
insulin resistance and lipodystrophy. Lipodystrophy is characterised by an increase in trunk 
fat (lipohypertrophy) and/or a decrease in limb fat (lipoatrophy). This thesis investigates the 
metabolic complications associated with ART, and develops simple anthropometric cut-points 
for identifying those with lipodystrophy. 
Data for this thesis comes from three datasets (a cross sectional study and two longitudinal 
studies), collected between 2007 and 2013. All datasets consisted of black HIV-infected men 
and women presenting to ART clinics in Cape Town. The same measurements were collected 
in all studies: anthropometry, self-reported lipodystrophy, dual-energy X-ray absorptiometry 
(DXA), blood pressure (BP), cholesterol and glucose. Longitudinal data were used to assess 
long-term ART exposure on BP, glycaemia, insulin secretion and anthropometric measures in 
women on ART.  We found that weight, waist circumference, and waist-hip ratio increased, 
limb skinfold thickness decreased, and the proportion of participants with hypertension and 
diabetes increased. Longitudinal data was used to describe changes in body fat distribution 
over a 24 month period. We found that women gained more overall weight and more regional 
fat in all areas compared to men. The risk of lipoatrophy was two-fold greater in men than in 
women.  
Simple, objective measures to define lipoatrophy and lipohypertrophy by comparing patient 
report to anthropometric and DXA-derived variables, were developed using cross sectional 
data. In women, the best predictors of lipoatrophy were triceps and thigh skinfold 
thicknesses, and for lipohypertrophy it was waist/hip ratio. Longitudinal data was used to 
validate the objective measures that were developed by comparing change in limb fat and 
trunk fat as measured by DXA to anthropometric variables. We showed that the best 
predictors of lipoatrophy in women were hip and mid-thigh circumference, and mid-arm 
circumference in men.  
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The thesis findings highlight the importance of early identification of these cardiometabolic 
risks in Africa. The development of anthropometric measures are of particular relevance in 
resource limited settings, where health professionals need simple and inexpensive methods 
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List of Abbreviations 
Abbreviations Full name 
3TC Lamivudine 
AIC Aikaike information criterion  
AIDS Acquired immune deficiency syndrome 
ART Antiretroviral therapy 
AUC Area under the curve 
AZT Zidovudine 
BMI Body mass index 
BP Blood Pressure 
CT Computerized tomography 
d4t Stavudine 
DAD Data collection on adverse events of anti-HIV drugs study 
Dio Oral disposition index 
DoH Department of Health 
DXA Dual-energy X-ray absorptiometry 
EFV Efavirenz 
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HIV Human immune deficiency virus 
HOMA-IR Homeostatic model assessment of insulin resistance 
HOMA-β homeostatic model assessment of beta cell function 
HOPS HIV Outpatient Study 
IFG Impaired fasting glucose 
IGI Insulinogenic index 
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IGT Impaired glucose tolerance 
IL-6 Interleuken-6 
IL-8 Interleuken-8 
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LDL Low density lipoprotein cholesterol 
LPV/r Lopinavir/ritonavir 
MACS Multicenter AIDS Cohort Study 
MRI Magnetic resonance imaging 
mtDNA Mitochondrial DNA 
NNRTI Non-nucleotide reverse transcriptase inhibitor 
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OGTT Oral glucose tolerance test 
PI Protease inhibitor 
QUICKI Quantitative insulin sensitivity check index 
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TDF Tenofovir 
TNF-α Tumour necrosis factor alpha  
VAT Visceral adipose tissue 
WHO World Health Organisation 
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Chapter 1. Introduction 
1.1 Context 
In 1981, acquired immune deficiency syndrome (AIDS) was first described [1] and by 1983 the 
human immune deficiency virus (HIV) was discovered [2]. Since the start of the HIV epidemic, 
78 million people have been infected with the virus. By the end of 2015, 36.7 million people 
were estimated to be living with HIV globally, and just under half of them (17 million) were 
accessing antiretroviral therapy (ART). Eastern and Southern Africa carry the greatest burden, 
with 19 million people estimated to be positive, and 10.3 million accessing ART [3].  
ART has improved the prognosis of people with HIV by suppressing HIV replication and 
restoring the patient’s immune system. In April 2004, as part of the South African Department 
of Health’s Operational Plan for Comprehensive HIV and AIDS Care, Management and 
Treatment [4], ART was made available to HIV-infected patients in the public health sector of 
South Africa, based on the following eligibility criteria: a CD4 ≤200 cells/mm3 or symptomatic, 
irrespective of stage, or with the World Health Organisation (WHO) stage IV. ART eligibility 
has since changed with the CD4 cut-point increasing to ≤350 cell/mm3 in 2011 and to ≤500 
cell/mm3 in 2015 [5]. The CD4 threshold was removed in September 2016. The adult first-line 
ART regimen comprises two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-
nucleoside reverse transcriptase inhibitor (NNRTI), while the second-line ART regimen 
comprises two NNRTIs and a protease inhibitor (PI). Patients were changed to the second-line 
ART treatment regimen if they experienced virologic failure as defined by two consecutive 
viral loads >1000 copies/mL [4]. In South Africa, the initial first-line regimen included 
stavudine, which was changed to tenofovir in 2010 due to stavudine’s toxicity [6]. Since those 
early days, ART coverage has increased to such an extent that by the end of 2015, 3.4 million 
South Africans were receiving ART [3]. 
Metabolic complications of ART 
ART has undoubtedly improved the quality of life and extended the life expectancy of those 
infected with HIV [7]. It is estimated to have prevented the death of 7.6 million people globally 
13 
 
[8]. However, the use of ART is also associated with a number of adverse effects which 
compromise adherence, leading to drug resistance, and can cause considerable morbidity and 
even mortality [9]. As HIV-infected patients on ART are living longer, the prevalence of a 
number of metabolic complications have increased [10].  
Several metabolic complications, including dyslipidaemia, dysglycaemia, insulin resistance, 
changes in body fat distribution, hypertension and hyperlactatemia are found in patients on 
ART [11-14]. These metabolic complications are thought to be related to the use of specific 
antiretroviral agents or to classes of antiretrovirals [13,15], and have been well documented 
in high-income countries. Limited data is available from low- and middle-income countries 
[16].Dyslipidaemia is commonly found in HIV infection, with and without the use of ART.  In 
the Multicenter AIDS Cohort Study (MACS), HIV-infected patients, prior to the introduction of 
ART, exhibited lower levels of total cholesterol, low-density lipoprotein (LDL) cholesterol and 
high density lipoprotein (HDL) cholesterol. After initiation of ART, total cholesterol and LDL 
cholesterol increased, while HDL cholesterol remained low [17]. Other studies have similarly 
found that untreated HIV-infected patients have an increased risk of low total, LDL and HDL 
cholesterol compared to HIV negative controls [18]. However, a systematic review by Dillon 
et al. [16], of studies from sub-Saharan Africa, found that HIV-infected individuals who were 
ART-naive had higher triglyceride levels and lower HDL levels that those who were uninfected, 
while ART treatment was associated with higher levels of LDL and HDL cholesterol. Changes 
in lipid profiles have been linked to specific antiretrovirals, which include PIs, thymidine 
analogue NRTIs, as well as NNRTIs [16,19,20]. PI-based regimens have been associated with 
persistent low levels of HDL cholesterol, as well as severely increased triglyceride levels [21] 
(though very uncommon), while the NRTIs stavudine and zidovudine are associated with 
increased levels of total and LDL cholesterol [22], and modestly elevated triglyceride levels 
[21].Regarding the NNRTI drugs, nevirapine has been shown to have a greater increase in HDL 
cholesterol and a decrease in the ratio of total cholesterol to HDL cholesterol than efavirenz 
[23].   
Hyperlactatemia, characterized by mild to moderate increases in blood lactate levels, has 
been reported in patients receiving NRTIs, and stavudine in particular [24,25]. Evidence from 
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high-income countries suggest that the majority of cases are either asymptomatic, or have 
only mild symptoms. The most severe form of hyperlactatemia, namely lactic acidosis, 
develops in a small proportion of patients and can be fatal [24,25]. As stavudine has been 
phased out, hyperlactatemia is no longer commonly found in patients treated with 
antiretroviral drugs.  
The relationship between hypertension and ART is inconsistent. Some early studies from high-
income countries reported an association between increased systolic blood pressure and 
duration of ART [26,27], while others reported a decreased risk of hypertension [28]. Evidence 
from smaller studies in low- and middle-income countries were equally inconsistent. A 
Nigerian study found no association between ART and hypertension [29], while studies from 
Tanzania [30], Nigeria [31], and Cameroon [32,33] found that HIV-infected adults on ART had 
an increased risk of developing hypertension when compared to HIV negative controls or ART-
naïve patients.  
Insulin resistance and diabetes mellitus are well-documented complications of ART [34]. 
Diabetes is preceded by insulin resistance and β-cell dysfunction and is characterised by a 
state of high blood glucose (hyperglycaemia) that develops when the pancreatic β-cell insulin 
secretion is unable to meet the insulin needs as determined by insulin resistance and 
carbohydrate intake [35]. Risk factors for insulin resistance include the pro-inflammatory 
effect of the HIV infection, the direct effect of some antiretrovirals, and the indirect 
consequences of HIV treatment, such as lipodystrophy [36]. The development of insulin 
resistance does not appear to be a class effect, but appears to be linked to specific drugs 
within the class of PIs [37], NRTIs [38,39] and NNRTIs [40]. Reports on the association between 
ART and dysglycaemia has been inconsistent. While studies from high-income countries found 
an increased risk of diabetes in patients on ART [39,41], a systematic review by Dillon et al., 
based on 52 datasets from 14 countries in sub-Saharan Africa, found no association between 
ART and fasting blood glucose levels [16]. The metabolic response to ART may be different in 
sub-Saharan Africa, where the majority of HIV-infected patients are black women in 
comparison to middle-aged white men in high-income countries [42]. Black women, when 
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matched to white women for body fatness, were more insulin resistant and had less visceral 
adipose tissue, which may indicate different pathophysiological processes [42,43].  
Lipodystrophy, also known as fat redistribution, is a well-documented metabolic complication 
of ART [44]. It is characterized by either subcutaneous fat loss, which is most noticeable in the 
face, limbs, and buttocks (lipoatrophy), central fat accumulation (lipohypertrophy) seen in the 
abdomen, breast or posterior neck (known as ‘buffalo hump’), or a combination of both 
[19,45,46]. The reported prevalence of lipodystrophy is varied as a result of differences in 
study designs, gender, ART regimens and duration of therapy [14]. Lipodystrophy has been 
shown to develop within four to six months of ART initiation, and continue to worsen over 
time [47]. There is limited research from low- and middle-income countries. However, the 
incidence is estimated to be high as these countries bear the greatest HIV burden, have the 
largest ART programmes in the world, and have only recently phased out stavudine which is 
a well-known cause of lipoatrophy.  
A systematic review by De Waal et al. [48] concluded that while lipoatrophy is an antiretroviral 
adverse drug reaction, lipohypertrophy appears not to be. Studies have shown that patients 
on ART have considerably less subcutaneous fat than those who are not on ART, and that fat 
loss increases with time on ART and can partially be reversed by switching medication [48]. 
Lipoatrophy is strongly associated with the use of the NRTIs, stavudine and zidovudine [48-
51], which has been shown to partially reverse after switching to tenofovir, abacavir or an 
NRTI-sparing regimen [48]. Lipoatrophy is thought to result from the impairment of 
mitochondrial function by NRTIs [52].   
Central fat accumulation or lipohypertrophy, occurs with equal prevalence in patients on ART, 
irrespective of their ART regimen, and does not reverse after switching to a different 
antiretroviral [48].  This suggests that central fat gain may be a consequence of treating the 
HIV infection, as the concentrations of inflammatory markers which cause wasting is 
normalized with treatment [48]. The development of lipohypertrophy is thought to be related 
to elevated levels of inflammatory cytokines [53], or to a surplus of energy that cannot be 
stored in atrophic subcutaneous depots [54].  
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The development of lipodystrophy has psychosocial and lifestyle implications. Psychological 
effects reported include feelings of depression, poor self-confidence and loss of self-esteem 
[55]. Due to the stigma of HIV, patients may not want to disclose their status, yet their 
changing body shape acts as an HIV identifier.  
The use of ART has rapidly increased in low- and middle-income countries during the last 
decade, and will continue to rise in these countries as they (1) follow the WHO’s 
recommendation to ‘test and treat’ [56] and, (2) continue to use zidovudine as part of their 
second-line ART treatment regimen [6]. Thus, the early identification of patients with these 
metabolic complications is becoming increasingly important.  
The diagnosis of lipodystrophy has been problematic, as both subjective and objective 
methods have been used, resulting in a number of varying definitions. Subjective methods of 
diagnosis include using patient perception and report [57,58], physician examination and 
report [59,60], and physician confirmation of patient report [45,61]. Objective measures 
often involve comparing measurement differences over time. Commonly used methods in 
research settings include computerized tomography (CT) scans [62,63], magnetic resonance 
imaging (MRI) [64], and dual-energy X-ray absorptiometry (DXA) scans [49,50,65]. These 
objective measures, while often used in research settings, is impractical in a clinical 
environment. Anthropometric and DXA-derived variables, such as fat mass ratio, have also 
been developed, in an attempt to provide standard measures for defining lipodystrophy  [66-
68].  
In low- and middle-income countries, where resources are limited, lipodystrophy is commonly 
diagnosed using self-report. However, results from studies comparing patient report to 
clinical examination have been contradictory as both high levels of agreement [46,69] and 
poor agreement [70-72] between these two methods have been reported. Moreover, when 
using different severity score ratings, the prevalence was vastly different [57,72]. 
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The literature review (Chapter 2) will focus on specific metabolic complications of ART 
relevant to the objectives of this thesis, namely hypertension, dysglycaemia and 
lipodystrophy.   
1.2 Problem statement and rationale 
Much of the information regarding the metabolic complications associated with the use of 
ART comes from high-income countries. There is limited data from sub-Saharan Africa. The 
frequency and prevalence of metabolic complications may be different in sub-Saharan Africa 
due to (1) poorer nutritional states resulting from poverty, malnutrition and chronic 
infections; (2) HIV-infected patients are predominantly young black women instead of middle-
aged men; and (3) black South African women are more insulin resistant and have less visceral 
adipose tissue and more subcutaneous adipose tissue than white women.  As findings show 
that lipoatrophy is an adverse antiretroviral drug reaction, while central fat gain may not be, 
further analysis is needed. Moreover, lipoatrophy is associated with the use of stavudine 
which has only recently been phased out of South Africa, and zidovudine, which is still being 
used. 
Criteria that were established to define lipodystrophy, did not include data from any African 
country and may therefore not be generalizable to South Africa. Many of these criteria also 
require access to laboratories and the use of expensive scanning equipment which is not 
available in South African Primary Healthcare facilities. As a result, there is a great need for a 
definition and measurement of lipoatrophy and lipohypertrophy that can be used with 
confidence in a South African setting. This measurement should be based on a simple, cheap 
tool that can be applied by health care staff at a community-based centre. 
1.3 Aims and Objectives 
The aim of this thesis is firstly to investigate metabolic complications associated with the use 
of ART which include hypertension, dysglycaemia, insulin resistance and lipodystrophy, and 
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secondly, to develop simple anthropometric cut-points to assist in identifying those with 
lipodystrophy. 
Specific objectives are: 
1. To assess the effects of long-term antiretroviral exposure on blood pressure, 
glycaemia, and anthropometric measures  
2. To describe changes in fat distribution over a 24 month period following ART initiation  
3. To investigate factors associated with changes in fat distribution 
4. To develop simple, objective measures to define lipoatrophy and lipohypertrophy 
using patient report as the reference standard 
5. To develop simple, objective measures to define lipoatrophy and lipohypertrophy 
using change in DXA measures as the reference standard  
1.4 Overview, context and structure of this thesis 
When data for this thesis was first collected in 2007, the public health ART programme in 
South Africa was in its third year. As per the National Department of Health Guidelines, the 
first-line ART treatment regimen consisted of stavudine, lamivudine and efavirenz or 
nevirapine. A second-line treatment regimen was available to patients who had failed on the 
first-line treatment. The second-line treatment regimen consisted of zidovudine, didanosine 
and lopinavir/ritonavir [6]. Routine monitoring of metabolic complications was only 
recommended for patients on a second-line treatment regimen. However, emerging evidence 
suggested that metabolic complications were occurring on non-PI-based treatment regimens 
as well. The prevalence of metabolic complications had been reported in studies from 
industrialised countries, but no large prevalence studies had been reported from sub-Saharan 
Africa, partly due to the recent access to ART.   
In addition to this chapter, this thesis includes a literature review, a methods chapter, four 
results chapters and a summary chapter. The literature review (Chapter 2) provides an 
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overview of specific metabolic complications of ART that are relevant to this thesis, namely 
hypertension, dysglycaemia and lipodystrophy. It focuses on African studies drawing special 
attention to gaps or ambiguity in our knowledge and understanding. 
The results chapters 4-7 are directly from manuscripts published or submitted for publication, 
which are included as appendices 1 and 2. Minor changes to the published versions have been 
made to ensure consistency throughout the thesis. Chapters 4 and 5 focus on the metabolic 
complications of ART. Chapter 4 (Appendix 1) addresses the first objective of the thesis, i.e. 
to assess the effects of long-term antiretroviral exposure on blood pressure, glycaemia, and 
anthropometric measures, using a sample of HIV-infected women on ART for a median of 16 
months at baseline. Measurements are collected at baseline and again approximately 5 years 
later. Chapter 5 addresses the second objective, i.e. to describe the changes in fat distribution 
over a 24 month period as well as the third objective, i.e. to investigate factors associated 
with changes in fat distribution.  We use clinical anthropometry and DXA to describe the 
changes in body fat distribution. Measurements are collected at baseline, 3 months, 6 
months, 12 months, 18 months, and 24 months after commencing ART.  
In chapters 6 and 7 we develop simple, objective measures for defining lipodystrophy. 
Chapter 6 (Appendix 2) addresses the fourth objective of the thesis, i.e. to develop simple, 
objective measures to define lipoatrophy and lipohypertrophy using patient report as the 
reference standard. DXA and anthropometric measures are obtained from a cross sectional 
sample of black HIV-infected South Africans on ART for a median of 16 months. Chapter 7 
addresses the fifth and final objective of the thesis, i.e. to use change in DXA measures as the 
reference standard to develop simple, objective measures to define lipoatrophy and 
lipohypertrophy. We compare change in limb fat and trunk fat as measured by DXA, to 
anthropometric variables in a sample of black South Africans on ART. Anthropometry and DXA 
measurements are collected at baseline, 3 months, 6 months, 12 months, 18 months, and 24 
months on ART.  
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The summary in Chapter 8 synthesises key findings from the thesis as a combined body of 
work. The strengths and limitations of the studies are considered as well as the implications 
for clinical practice, policy change and future research.  
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Chapter 2. Literature Review 
2.1 Overview 
This literature review forms the theoretical framework of the thesis. It starts by providing an 
overview of specific metabolic complications of ART, namely hypertension, dysglycaemia and 
lipodystrophy, before focusing on the assessment of lipodystrophy. It defines key terms, 
definitions and terminology as well as summarising key features of existing knowledge that 
are most relevant to the focus of the thesis.  The review is organised around the thesis 
objectives and addresses themes relevant to the results chapters. This review is not intended 
to be systematic but rather to represent key points in the literature.  It focuses on African 
studies drawing specific attention to gaps or ambiguity in our knowledge and understanding 
and is divided into 3 sections. 
Section 2.3 addresses the association between ART and hypertension, which is relevant to 
Objective 1 and provides background to Chapter 4. This section addresses the relationship 
between ART and hypertension as well as the proposed biological mechanisms.  Section 2.4 
addresses the association between ART and dysglycaemia, which is relevant to Objective 1 
and provides background to Chapter 4. Section 2.4.1 describes the measures of insulin 
resistance and β-cell function, while Section 2.4.2 investigates the relationship between HIV 
and insulin resistance, and ART and insulin resistance.  
Section 2.5 is the largest section and addresses the association between ART and 
lipodystrophy. It is relevant to Objectives 2-5, and provides background to Chapters 4-7. 
Section 2.5.1 provides an overview of the prevalence of lipodystrophy in high-income 
countries as well as in sub-Saharan Africa, while Section 2.5.2 provides the motivation for 
diagnosing lipoatrophy and lipohypertrophy separately. Section 2.5.3 investigates risk factors 
associated with lipodystrophy, while Section 2.5.4 describes the occurrence of other 
metabolic complications often seen with lipodystrophy. These sections provide background 
to Chapters 4 and 5.The final section, Section 2.5.5, provides an overview of subjective and 
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objective methods that have been used to assess lipodystrophy, lipoatrophy and 
lipohypertrophy, and provides the background to Chapters 6 and 7.  
2.2 Methodology of the literature review 
PUBMED was searched for work published during the last 10 years, i.e. between 2006 and 
2016. Results were limited to studies on adults that reported on hypertension, glucose 
dysregulation and changes in fat distribution resulting from exposure to ART. The search 
terms included ‘HIV’ or ‘human immunodeficiency virus’ and ‘ART’ or ‘HAART’ or 
‘antiretroviral’ or ‘ARV’. The search terms that were excluded were ‘child’ OR ‘children’ OR 
‘adolescent’ OR ‘infant’. Based on the section of the literature review that was being 
researched, additional terms were added, and specified to appear in the abstract. The 
additional terms added for Section 2.3 included ‘hypertension’ or ‘blood pressure’ or ‘systolic’ 
or ‘diastolic’ or ‘BP’, and additional terms for Section 2.4 included ‘glucose’ or ‘dysglycaemia’ 
or ‘dysglycemia’ or ‘diabetes’ or ‘insulin’. The additional terms added for Section 2.5 included 
‘lipoatrophy’, ‘lipohypertrophy’, ‘lipodystrophy’, ‘fat redistribution’, ‘fat distribution’, and 
‘body composition’. References listed in papers identified were also checked for further 
publications to include. The intention of this literature review is to represent key points in the 
literature and is not systemic or exhaustive.  
2.3 Antiretroviral therapy and Hypertension  
The relationship between ART and hypertension has been investigated in small and large 
studies from high-income countries. The results were inconsistent. A Norwegian study of 380 
patients who were mostly men, found that patients on ART had a higher prevalence of 
hypertension than those who were ART-naïve. However the association was not statistically 
significant [1]. In 2003, the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study, 
using pooled data from 10 cohorts comprising 17170 participants, investigated the role of ART 
on changes in blood pressure and the development of hypertension.  The DAD study found 
no association between hypertension and ART. Instead, they reported that cumulative 
exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was associated with a 
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slight decreased risk of hypertension, which varied according to the threshold used to define 
hypertension [2]. In 2005, the Multicenter AIDS Cohort (MAC) study, using a cohort of 5578 
men that were followed between 1984 and 2003, investigated the association of 
hypertension with HIV infection and ART. The MAC study found that prolonged use of ART 
was associated with an increase in the prevalence of hypertension. After 2 or more years on 
ART, the odds of systolic hypertension (defined as systolic blood pressure > 140 mmHg) 
increased significantly, while diastolic blood pressure remained the same [3].  
Evidence from smaller studies in low- and middle-income countries was equally inconsistent. 
A Nigerian study of 403 men and women, found no association between ART and 
hypertension [4], while cross sectional studies from Tanzania [5], Nigeria [6], and Cameroon 
[7,8] found that HIV-infected adults on ART had an increased risk of developing hypertension. 
All studies defined hypertension similarly. 
Two systematic reviews [9,10] examined the association between ART and hypertension. In 
2013, Dillon et al. [9] assessed possible associations between HIV, ART and cardiometabolic 
traits in sub-Saharan Africa. Using data from 14 countries and 2087 participants, the 
systematic review found no association between ART use and systolic or diastolic blood 
pressure, in both adjusted and unadjusted models. More recently, Nduka et al. [10], using 
data from 21 countries and 44903 HIV-infected patients from high-, low- and middle-income 
countries, concluded that ART exposure was associated with higher systolic and diastolic 
blood pressure levels and an increased risk of hypertension, regardless of ART regimen or 
duration.  
The biological mechanism explaining the association between ART and hypertension is 
unclear. Increased blood pressure levels among HIV-infected patients on ART have been 
linked to damage to the endothelial lining of blood vessels [10]. As the endothelial cells in 
blood vessels play a key role in cardiovascular regulation by producing vasoactive agents 
which include vasodilators, dysfunction of the epithelial lining could result in hypertension 
[11].  
An alternative theory [12] proposes that antiretrovirals such as nucleoside reverse 
transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) have a mediating effect on blood 
pressure by causing changes in body fat distribution [13,14], which in turn leads to increased 
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blood pressure levels [15]. This theory appears to have merit as studies have found that 
hypertension was independently associated with both lipoatrophy [16] and an increased 
waist circumference in HIV-infected patients on ART [12,16-18]. However, a systematic review 
by De Waal et al. [14] concluded that central fat gain seems not to be an antiretroviral adverse 
drug reaction, but rather the result of treating the HIV infection, which normalises the 
concentrations of inflammatory markers that cause wasting (refer to section 2.5.2). While 
central fat gain seems to signify a return to health, it is nonetheless associated with an 
increased risk of hypertension, which in turn is associated with an increased risk of 
cardiovascular disease [19].  
As ART coverage rates increase in low- and middle-income countries during the coming years, 
so may the burden of antiretroviral-associated hypertension.  Even small increases in blood 
pressure may result in considerable public health impact on the prevalence of cardiovascular 
disease [19]. There is thus a need for risk factor assessment before ART initiation, as well as 
regular monitoring while on treatment. The early detection and management of hypertension 
is essential for the prevention of cardiovascular events.  
2.4 Antiretroviral therapy and Dysglycaemia 
Dysglycaemia refers to any disorder in the metabolism and regulation of blood glucose levels, 
and includes insulin resistance and β-cell dysfunction. Type 2 diabetes mellitus is preceded by 
both these disorders and is characterised by a state of high blood glucose (hyperglycaemia) 
that develops when the pancreatic β-cell insulin secretion is unable to meet the insulin needs 
as determined by insulin resistance and carbohydrate intake [20]. Insulin resistance and 
diabetes are well-documented complications of ART [21]. 
2.4.1 Measures of insulin resistance and β-cell function 
The hyperinsulinaemic euglycaemic clamp is considered the gold standard diagnostic test to 
assess insulin resistance [22]. It involves the simultaneous infusion of insulin and a glucose 
solution into a peripheral vein, while frequently monitoring the blood glucose levels.  The 
amount of glucose solution required to maintain normal blood glucose levels at a steady state 
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is measured. Both hypo- and hyperglycaemia can be detected. As this technique is time 
consuming and costly, it is typically used in research settings or small studies [23].  
The oral glucose tolerance test (OGTT), with a fasting blood sample drawn immediately before 
ingesting the glucose solution and another sample drawn 120 minutes after ingestion [24], is 
predominantly used in large epidemiological studies as a tool to diagnose diabetes, but is also 
used to identify impaired glucose tolerance in non-diabetic populations. An OGTT can also be 
used to evaluate both β-cell function and insulin resistance, as the blood glucose and insulin 
responses obtained from this test are able to reflect the ability of pancreatic β-cells to secrete 
insulin as well as to assess the sensitivity of tissues to insulin [25]. Criteria for the diagnosis of 
diabetes and impaired glucose regulation have been developed by the Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus [26,27]. The Expert Committee 
acknowledged that some individuals had glucose levels that did not meet the criteria for 
diabetes, but were higher than normal, and were thus considered to be at risk of developing 
diabetes. Both the fasting blood glucose as well as the 120 minute glucose measure can be 
used to diagnose diabetes. In addition, fasting blood glucose is used to diagnose impaired 
fasting glucose (IFG), while the 120 minute glucose is used to diagnose impaired glucose 
tolerance (IGT) (Table 1).  In epidemiological studies, patients that are diagnosed with 
diabetes using the OGTT, are referred to healthcare facilities for assessment, confirmation of 
diagnosis and management.  
Table 1. Diagnostic criteria for glucose abnormalities 
Glucose abnormality Diagnostic measure Range  
Impaired fasting glucose (IFG) Fasting plasma glucose  5.6-6.9 mmol/l 
Impaired glucose tolerance (IGT) 2hr plasma glucose during OGTT  7.8-11.0 mmol/l 
Diabetes Fasting plasma glucose  ≥ 7mmol/l 
 2hr plasma glucose during OGTT ≥ 11.1 mmol/l 
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A number of indices have been developed to measure β-cell function and insulin 
sensitivity/resistance using either fasting samples or other measures of insulin and glucose 
taken at various time points during the OGTT [24,28,29]. In addition to the insulin and glucose 
measures, the McAuley index uses the fasting triglyceride and the Stumvoll index uses BMI 
and age [30,31]. Table 2 shows some of the indices used to assess β-cell function and insulin 
sensitivity/resistance obtained from results of an OGTT, as well as the calculation and 
description of each index.  
High homeostatic model assessment of insulin resistance (HOMA-IR) and low homeostatic 
model assessment of beta cell function (HOMA-β) are associated with an increased 
prevalence of insulinogenic index (IGI) and risk of developing diabetes [28], while a low oral 
disposition index (DIo) level is considered an early marker of inadequate β-cell function [29]. 
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Table 2. Some of the indices used to measure β-cell function and insulin sensitivity/resistance 
[30-32] 






A measure of the insulin 
response to glucose 
 
HOMA-β (20 x fasting insulin)/(fasting insulin-3.5) 





ΔGlucose0–30) × (1/fasting insulin) 
A measure of the rise in 
insulin secretion in 





1283 + 1.829 X I30 – 138.7 x G30 + 3.772 I0 





Fasting Insulin-1 1/ fasting insulin 




to insulin ratio 
fasting glucose/fasting insulin 





1/ 120 min insulin 
A measure of insulin 
sensitivity 
 
HOMA-IR (fasting glucose × fasting insulin)/22.5 
A measure of insulin 
resistance 
 
QUICKI Index 1/(log fasting insulin + log fasting glucose)  




10000/√fasting glucose x fasting insulin x Gmean x 
Imean 
A measure of insulin 
sensitivity 
 
Raynaud Index 40/fasting insulin 
A measure of insulin 
sensitivity 
 
McAuley Index  e2.63-0.28 ln(fasting insulin) ln(fasting triglycerides) 





2/ [(fasting insulin x fasting glucose) + 1] 




Sib = 108/ (fasting insulin x fasting glucose x VD) 
Si2h = 108/ (120 min insulin x 120 min glucose x 
VD) 
SiM = (0.137 x Sib) + Si2h/2 




0.222 – 0.00333 x BMI – 0.0000779 x 120 min 
insulin – 0.000422 x age 
A measure of insulin 
sensitivity that utilises 
demographic data 
IGI – insulinogenic index; HOMA-β – homeostatic model assessment of beta cell function; DIo – oral disposition 
index; HOMA-IR – homeostatic model assessment of insulin resistance; QUICKI – quantitative insulin sensitivity 
check index; Gmean – mean plasma glucose concentration during OGTT; Imean – mean plasma insulin concentration 
during OGTT; VD – glucose distribution volume calculated using a monocompartmental model 
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2.4.2 Development of insulin resistance 
Insulin resistance was one of the first metabolic complications of ART to be reported [21]. In HIV-
negative individuals, factors contributing to the development of insulin resistance include genetic 
factors, physical inactivity and obesity. HIV-infected individuals on ART have the same risk factors in 
addition to HIV-related risk factors, which include the pro-inflammatory effect of the HIV infection, 
the direct effect of antiretrovirals, and the indirect consequences of HIV treatment, such as 
lipodystrophy [33].  
Effect of HIV on insulin resistance 
Before the introduction of ART, insulin resistance was rarely reported in HIV-infected 
individuals. Initially, small cross sectional studies from high-income countries demonstrated 
similar or slightly increased insulin sensitivity in HIV-infected individuals compared to 
uninfected controls [34,35]. However, later studies found that HIV-infected individuals were 
developing insulin resistance in the absence of, or prior to initiation of ART [36-38]. The MAC 
Study reported a lower QUICKI index (indicating decreased insulin sensitivity or insulin 
resistance) and higher fasting insulin levels in HIV-infected men who were not exposed to 
ART, and proposed an association between HIV infection and hyperglycaemia [39]. The 
mechanism responsible for altering insulin sensitivity in HIV-infection is thought to be related 
to an overproduction of pro-inflammatory cytokines, which are known to play a role in the 
development of insulin resistance in other conditions involving inflammation such as obesity 
and diabetes. In HIV-infection, infected T-cells and adipose tissue produce increased amounts 
of tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8), which 
cause inflammatory insulin resistance and have been linked to increased levels of HOMA-IR 
[38].  
Effect of ART on insulin resistance  
The association between ART and insulin resistance is well documented, and is known to 
affect the organs and tissues that are normally involved in glucose regulation, namely adipose 
tissue, skeletal muscle and the liver, resulting in insulin resistance [40,41].  The development 
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of insulin resistance does not appear to be a class effect, but appears to be linked to specific 
drugs within the class of PIs [42], NRTIs [39,43] and more recently NNRTIs [44].  
The first antiretrovirals found to be associated with insulin resistance, were the first-
generation PIs, indinavir [42,45] and ritonavir [46]. These PIs are thought to cause insulin 
resistance by blocking insulin-stimulated glucose uptake in adipocytes via inhibition of the 
glucose transporter GLUT4 [33,47] (Figure 1). While indinavir is no longer used, ritonavir 
remains widely used with other PIs, such as the commonly prescribed co-formulated 
lopinavir/ritonavir combination [23]. Whereas the previously prescribed full dose ritonavir 
induced insulin resistance [48], the far lower doses prescribed for boosting have been shown 
to have little effect on insulin sensitivity [49]. The relationship between lopinavir and insulin 
resistance is still unclear as Dube et al. [50] reported that lopinavir/ritonavir did not induce 
insulin resistance, while Taylor et al. [49] suggested that lopinavir was responsible for the 
insulin resistance observed in short term studies of lopinavir/ritonavir. New generation PIs, 
atazanavir, tipranavir and darunavir appear to have little or no effect on insulin sensitivity 
[23,51,52]. Although inhibition of glucose transport is considered the main mechanism for 
insulin resistance, prolonged exposure to PIs affect cellular insulin signalling, leading to a 
change in insulin sensitivity and indirectly changing glucose uptake [41]. 
Figure 1. Diagrammatic representation of mode of action of insulin, and mechanism of insulin 





Indirect effect of ART on insulin resistance 
NRTIs, particularly stavudine and zidovudine, have been implicated in the development of 
insulin resistance and diabetes. The MAC study [39], reported a strong association between 
stavudine and insulin resistance, while the DAD study [43] did not measure insulin resistance 
but reported that stavudine and zidovudine were associated with the development of 
diabetes. Findings from sub-Saharan Africa have been contradictory. In a South African 
population, Dave et al. [53] found that the incidence of dysglycaemia in ART and ART-naïve 
patients were similar, while a study from Ethiopia [54] reported that diabetes was associated 
with increasing age and duration on ART. A Ugandan study [55] reported that stavudine had 
a protective effect on hyperglycaemia, while also reporting that the proportion of patients 
with borderline hyperglycaemia and diabetes were similar on stavudine and zidovudine. More 
recently Karamchand et al. [44], based on a cohort of 56298 HIV-infected South Africans on 
ART, reported an increased incidence of diabetes in patients on stavudine, and to a lesser 
extent, zidovudine.  
The NRTIs stavudine and zidovudine are linked to the development of subcutaneous 
lipoatrophy, thought to be mediated by inhibiting mitochondrial polymerase-gamma in 
adipose tissue.  Apoptotic adipocytes release free fatty acids which accumulate in the liver 
and skeletal muscle, resulting in peripheral insulin resistance [39]. Independent of changes in 
body composition, NRTIs cause mitochondrial toxicity in skeletal muscle, which affects 
glucose regulation and causes secondary insulin resistance [23,41]. 
 Historically, NNTRIs such as efavirenz and nevirapine, were not associated with the 
development of insulin resistance or diabetes as reports from high-income countries [23,43] 
suggested minimal changes with little clinical significance. However, in sub-Saharan Africa, 
reports of an association between efavirenz and dysglycaemia have emerged. In 2011, Dave 
et al. [53] reported a significant association between efavirenz use and dysglycaemia. In a 
recent study, Karamchand et al. [44] reported an increased risk of developing diabetes in a 
large cohort of South African patients treated with efavirenz compared with nevirapine. The 
mechanism whereby efavirenz results in insulin resistance is unknown, but has been 
postulated to involve mitochondrial toxicity, as well as being mediated though changes in fat 
distribution [56].   
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Figure 2. Potential causes of insulin resistance in HIV-infected patients on ART [23] 
 
 
The development of insulin resistance in HIV-infected individuals on ART results from direct 
and indirect mechanisms, as well as other predisposing factors related to genetics, obesity 
and inactivity (Figure 2) [23]. The PI co-formulated lopinavir/ritonavir, the NRTI zidovudine 
and NNRTI efavirenz are still being used in low- and middle-income countries such as South 
Africa [57], while stavudine has only recently been phased out. The continued use of drugs 
that are directly and indirectly associated with the development of insulin resistance and 
diabetes, is predicted to increase the incidence of dysglycaemia and diabetes as the number 
of HIV-infected treated with ART continues to grow, and the time spent on ART continues to 
increase. 
2.5 Antiretroviral therapy and Lipodystrophy 
Lipodystrophy, also known as fat redistribution, is commonly reported in HIV-infected 
patients taking ART. It is characterized by either subcutaneous fat loss (lipoatrophy), which is 
most noticeable in the face, limbs, and buttocks, or fat accumulation (lipohypertrophy) seen 
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in the abdomen, breast or posterior neck, or a combination of both [58]. HIV-related 
lipodystrophy was first described after the introduction of PIs in the late 1990’s [21], but was 
later found to occur in patients receiving non-PI regimens as well [59,60].  
2.5.1 Prevalence of lipodystrophy  
High-income countries  
The relationship between ART and changes in fat distribution has been well studied in high-
income countries. The first studies to report on lipodystrophy were based on cross sectional 
study designs and mostly used patient report or clinical examination to diagnose 
lipodystrophy, lipoatrophy and lipohypertrophy (Table 3). Drug regimens used were varied, 
with the majority of patients taking a PI-based ART regimen. The prevalence of lipodystrophy 
reported in these studies were wide-ranging, possibly due to different diagnostic criteria, drug 
regimens and demographic factors [61]. In 2001, based on 868 men-who-have-sex-with-men, 
the MAC study reported that 25-30% of HIV-infected men had lipoatrophy, and that 40% had 
a combination of lipoatrophy and central fat gain [62]. The CISAI study, consisting of 1480 
patients recruited from 10 infectious disease departments in Italian hospitals between 1997 
and 1999, reported a relatively low lipodystrophy prevalence of 7.5-13.6%, depending on the 
ART regimen used [63], while the HIV Outpatient Study (HOPS), consisting of 1077 patients 
recruited from 8 HIV treatment clinics in 7 cities in the USA in 1998 [60], reported that 49% 
of patients showed one or more signs of fat redistribution. Between 1997 and 1998, 614 HIV-
infected patients were recruited from French health care centres [64]. Lipodystrophy was 
reported in 62% of participants, with 21% diagnosed with only lipoatrophy and 17 % with only 
lipohypertrophy. In a large Australian study [65] consisting of 1348 participants recruited 
between 1998 and 1999, lipodystrophy was diagnosed in 53% of participants.  
Sub-Saharan Africa 
In sub-Saharan Africa, ART slowly became available in the early 2000s. By 2004, when the cost 
of antiretrovirals started to decrease [66], ART become more readily available, but was still 
governed by eligibility criteria.  The most frequently used ART regimen consisted of stavudine, 
lamivudine and nevirapine, with very few patients initiating ART with a PI-based regimen [67], 
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partly due to its cost [68]. Limited research (Table 4) is available on the association between 
ART and lipodystrophy in sub-Saharan Africa, with the largest studies coming from South 
Africa [69-71] and Rwanda [72]. The majority of studies used a cross sectional design and, 
unlike studies from high-income countries, consisted mostly of black women in their mid-
thirties. Most studies reported on the prevalence of lipodystrophy which ranged from as low 
as 7.2% in a large Rwandan sample (n=2190) using a longitudinal study design [72] to as high 
as 68% in a small Ethiopian study (n=313) [73]. A few studies reported on the prevalence of 
lipoatrophy which ranged from less than 2% in a large South African study consisting of 2835 
men and women [71] to 26% in a small Nigerian study of 288 men and women on ART for 
more than 6 months [74]. Even fewer studies reported on lipohypertrophy which ranged from 
11% to 36% [69,75,76]. 
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Table 3. Summary of selected studies from high-income countries measuring change in fat distribution 
Country Study design n Population Assessment method 
ART regimen and 
duration 
Fat distribution 
Australia [21] Cross 
sectional 
study 
195 Majority men, mean 
age = 40 years 
Patient report and 
clinical examination 
PI-based ART regimen Lipodystrophy = 64% 
Australia [77] Cross 
sectional 
study 
159 Only men  Patient report; DXA 
measures and lipid 
profile 
PI-based ART regimen 
with d4T or AZT 
Patient reported 
lipodystrophy (fat loss in 
arms and legs with 
abdominal fat gain) = 
18.2%; Patient 
reported lipoatrophy = 
20%; DXA and lipid 
based lipodystrophy = 
54.7% 
Australia [78] Cross 
sectional 
study 
1348 Majority men, mean 
age = 40 years 
Clinical examination Various ART regimens 
including PI-based 
Lipodystrophy = 53% 
Denmark [79] Cross 
sectional 
study 
168 Only men, median age 
= 43 years 
Patient report and 
clinical examination 
2 NRTIs + ritonavir or 
ritonavir + sequinavir 
or nelfinavir 
Lipoatrophy = 10%; 
Abdominal obesity = 
43% 
France [64] Cross 
sectional 
study 
614 Majority men Clinical examination  Various ART regimens, 




Italy [63] Cross 
sectional 
study 
1480 Majority men, mean 
age = 37 years 




ritonavir, ritonavir + 
saquinavir and 9 other 
combinations; mean 
Lipodystrophy =7.5-
13.6%; Lipoatrophy = 
3.4-7.4%; 
Lipohypertrophy = 2.7-




observation time = 22 
months 
USA [60] Cross 
sectional 
study  
1077 Majority white men, 
mean age = 41 years 
Patient report and 
clinical examination 
Various ART regimens 1 or more signs of fat 
redistribution = 49%; 
Lipoatrophy = 15.9%; 
Lipohypertrophy = 
9.7% 
USA [62] Cross 
sectional 
868 Only men Patient report and 
anthropometry 
PI-based ART regimen Lipoatrophy = 25-30%; 
Combination of 
lipoatrophy and 
lipohypertrophy = 40% 
DXA - Dual energy X-ray absorptiometry; d4T – stavudine; AZT - zidovudine
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Table 4. Summary of selected studies from sub-Saharan Africa measuring changes in fat distribution 
Country Study design n Population Assessment method 







243 Majority women, 
mean age = 39 years 
Patient report with 2 
definitions based on 
severity 
d4T/AZT + 3TC + 
NVP/EFV for >6 
months 
Lipodystrophy = 
18.6%; Lipoatrophy = 
2-9%; Lipohypertrophy 
= 11=36% 
Ethiopia [73] Cross sectional 
study 
356 Majority women Patient report and 
clinical examination 
d4T-based ART 
regimen > 1 year 
Lipodystrophy =68.3% 
Ethiopia [80] Cross sectional 
study 
313 Majority women, 
mean age = 41 years 
Patient report and 
clinical examination 
ART > 6 months Lipodystrophy = 12.1% 
Nigeria [74] Cross sectional 
study 
288 Majority women, 
mean age = 39 years 
Patient report and 
clinical examination 
using a standard 
questionnaire 
d4T- or AZT- or TNF-
based ART regimen 
for > 6 months 
 
Lipodystrophy = 26% 
Rwanda [72] Longitudinal 
study with 1.5 
years median 
follow-up time 
2190 Majority women, 
mean age = 38 years 
Patient report and 
clinical examination 
using a standard 
questionnaire 
d4T + 3TC + NVP Lipodystrophy = 7.2% 
Rwanda [76] Cross sectional 
study 
409 Majority women, 
mean age = 38 years 
Patient report and 
clinical examination 
using a standard 
questionnaire 
d4T + 3TC + NVP > 1 
year 
Lipodystrophy = 
34.2%; Lipoatrophy = 
9.8%; Lipohypertrophy 
= 19.6% 
Rwanda [81] Cross sectional 
study 
571 Majority women, 
mean age = 38 years 
Patient report and 
clinical examination 
d4T + 3TC + NVP > 6 
months 
Lipodystrophy = 34% 





mean age = 35 years 
Patient report and 
clinical examination 
using a standard 
questionnaire 
d4T-based regimen 
for > 12 months 
Lipoatrophy = 12.2% 
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Senegal [83] Case control 
study 
180 Majority women Clinical examination d4T-, AZT- and PI-
based regimens for 4-
9 years 
Lipodystrophy = 












median time on ART = 
19 months 





3910 58% women Physician report d4T + 3TC + NVP/EFV 
> 12 months 





2835 70% women, > 15 
years  
Physician report d4T + 3TC + EFV > 15 
months 





479 Majority women, 
mean age = 35 years 
Patient report and 
clinical examination 
d4T-based regimen > 
12 months 




study with 1 
year follow-up 
time 
230 64% women, mean 
age = 35 years 
Patient report d4T + 3TC + EFV > 12 
months 
Lipodystrophy = 11.7% 
d4T – stavudine; AZT – zidovudine; 3TC – lamivudine; EFV – efavirenz; NVP – nevirapine; TNF - tenofovir
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Differences between high-income countries and sub-Saharan Africa 
The prevalence of lipodystrophy is wide-ranging in both high-income countries and sub-
Saharan Africa (Table 3 and 4). Some of this can be attributed to the subjectivity of self-report 
and clinical examination (refer to section 2.5.5). However, differences in populations and drug 
regimens play a major role when comparing high-income countries to sub-Saharan Africa, as 
the HIV-infected populations in these two regions are different. In high-income countries the 
majority of HIV-infected are men-who-have-sex-with-men, while the majority of HIV-infected 
in sub-Saharan Africa are black women. As black South African women have less visceral fat 
than white South African women [86], the prevalence of fat redistribution in high-income 
countries should not be expected to be similar to the prevalence in sub-Saharan Africa. 
Furthermore, ART drug regimens also differed – high-income countries primarily used PI-
based regimens, while in sub-Saharan Africa, due to the higher cost of PIs compared to NRTIs 
[68], the majority of ART regimens were NRTI-based, including stavudine. As stavudine is 
without doubt responsible for the development of lipoatrophy [14], and stavudine has only 
recently been phased out in sub-Saharan Africa [87], the prevalence in sub-Saharan Africa is 
expected to be high. 
2.5.2 Lipodystrophy versus lipoatrophy and lipohypertrophy 
While the majority of studies reported on the prevalence of lipodystrophy, which referred to 
peripheral lipoatrophy, or central fat gain (lipohypertrophy), or a combination of both, recent 
findings have highlighted the need to differentiate between the two syndromes. In 2013, a 
systematic review by De Waal et al. [14] concluded that lipoatrophy was an adverse 
antiretroviral drug reaction, while lipohypertrophy appeared to be a consequence of treating 
the HIV infection. Based on 27 prospective studies that used objective methods [dual energy 
X-ray absorptiometry (DXA), computerised tomography (CT), or magnetic resonance imaging 
(MRI)] to assess fat distribution over a minimum of 24 weeks, the authors concluded that 
lipoatrophy was strongly associated with the use of NRTIs, specifically stavudine and 
zidovudine, and that subcutaneous adipose tissue (SAT) was lower in patients on ART 
compared to controls and decreased with decreasing time on ART. In addition, they found 
that when efavirenz was combined with NRTIs, the risk of limb fat loss was greater than when 
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combined with PIs [14].  Lipoatrophy is thought to occur as a result of mitochondrial toxicity 
in adipose tissue. NRTIs inhibit DNA polymerase gamma, which is needed for the replication 
of mitochondrial DNA (mtDNA). The subsequent depletion of mtDNA results in mitochondrial 
dysfunction in adipose tissue [88-90]. 
The results of the systematic review by De Waal et al. [14] suggested that lipohypertrophy 
was a consequence of treating the HIV infection as visceral adipose tissue (VAT) and trunk fat 
were no different in participants on ART compared to controls, nor was central fat gain 
associated with specific antiretrovirals. The authors hypothesised that lipohypertrophy 
developed when the concentrations of inflammatory markers that are known to cause 
wasting were normalised, as a consequence of treating the HIV infection.  
2.5.3 Risk factors associated with lipodystrophy 
Several risk factors for lipodystrophy have been identified. The most commonly reported 
include the use of specific antiretrovirals, duration of ART, sex and BMI. Early studies that did 
not differentiate between lipoatrophy and central fat gain, reported an association between 
PI use and fat redistribution. However, it soon became evident that lipoatrophy occurred in 
patients who had never been exposed to a PI-based regimen.  The HOPS study [60] reported 
a strong association between lipoatrophy and both stavudine and indinavir, as well as more 
than 2 years of PI exposure.  The CISAI study in Italy [63] concluded that lipodystrophy was 
associated with the PIs ritonavir and indinavir, as well as noting an association between 
stavudine and lipoatrophy. A number of smaller studies from high-income countries also 
reported associations between lipodystrophy and PI use [21,64], and stavudine and 
peripheral fat loss [79,91].  
In sub-Saharan Africa, where PIs were rarely used, several studies reported an association 
between stavudine and lipodystrophy, especially lipoatrophy [69-72,76]. In Rwanda, patients 
on a stavudine-containing regimen had a three times higher prevalence of lipoatrophy 
compared to those on a zidovudine-containing regimen [76], while in Nigeria, 46% of patients 
taking stavudine developed lipoatrophy compared to 31% of those on zidovudine [74]. 
Studies have also shown that lipoatrophy increases with increasing duration [76] and dose of 
stavudine [71], and is partially reversed after switching to abacavir, tenofovir or an NRTI-
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sparing regimen [14]. As evidence of the toxic effect of stavudine increased, the World Health 
Organisation recommended that the dosage for adults and children be reduced from 40mg 
to 30mg [92]. Studies comparing the effects of the 30mg versus the 40mg stavudine dosage, 
found that the 30mg dosage resulted in fewer toxic effects, with similar viral load suppression, 
when compared to the 40mg dosage [71,75]. In 2010 the World Health Organisation 
recommended that stavudine be discontinued and replaced with tenofovir. However, due to 
the higher cost of tenofovir and stockpiles of stavudine, low- and middle-income countries 
continued to use stavudine for several more years [92]. 
The relationship between fat redistribution and gender has been contradictory. While several 
studies in sub-Saharan Africa found a higher prevalence of lipoatrophy in women compared 
to men [69,76], a study from Nigeria [74] reported a higher prevalence in men, and a study 
from Cameroon reported an equal prevalence in men and women [75]. The relationship 
between BMI and lipoatrophy is also contradictory. Studies from Rwanda [76,82] reported 
that a higher baseline BMI was associated with lipoatrophy, while a Nigerian study [74] 
reported an association between lower baseline BMI and lipoatrophy.  
2.5.4 Implications of lipodystrophy  
The development of lipodystrophy is associated with cardiometabolic risk factors such as 
dyslipidaemia and dysglycaemia [93]. Patients with lipodystrophy may develop impaired 
glucose tolerance and insulin resistance [43,53,94] as well as increased levels of triglycerides 
[95] and decreased levels of HDL cholesterol [96]. As insulin resistance is often reported 
before lipodystrophy, it is thought to be involved in the development of lipodystrophy. 
However, others have suggested that lipodystrophy, particularly central fat gain, is partly 
responsible for the development of insulin resistance [39,97].  
The development of lipodystrophy has psychosocial and lifestyle implications as well. As a 
result of the stigma associated with HIV-infection, patients may not want to disclose their 
status, yet their changing body shape acts as an HIV identifier. Patients have reported 
psychological effects which include feelings of depression, poor self-confidence and loss of 
self-esteem [98].  
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The prevalence of lipodystrophy, specifically lipoatrophy, is high in low- and middle-income 
countries as stavudine has only recently been phased out, and zidovudine continues to be 
used.  
2.5.5 Assessment of lipodystrophy 
Lipodystrophy has been diagnosed using both subjective and objective methods, resulting in 
challenges in the diagnosis and assessment of its prevalence and incidence. Subjective 
methods of diagnosis include using patient perception and report, physician examination and 
report and physician confirmation of patient report.  Objective measures often involve 
comparing measurement differences over time. Commonly used methods include CT scans, 
MRI, and DXA scans. Anthropometric and DXA-derived variables, such as fat mass ratio, have 
also been developed, in an attempt to provide standard measures for defining lipodystrophy.  
Subjective assessment methods 
The majority of studies, both from early high-income countries as well as later studies from 
sub-Saharan Africa (Table 3 and 4), used subjective measures to diagnose lipodystrophy. 
Studies generally used one of the following methods: (1) only patient self-report, (2) patient 
self-report and examination by a clinician, (3) only examination by a clinician or (4) patient 
self-report confirmed by examination by a clinician. Questionnaires were commonly used to 
capture the change in fat distribution. The most frequently used questionnaire was developed 
for the HOPS study [60], in which 1077 patients completed a survey and were examined by 
their physician. Body areas evaluated included the abdomen, dorso-cervical spine, arms, legs, 
hips, buttocks and face. Changes were graded as ‘subtle’, ‘moderate’ or ‘severe’, and based 
on agreement between the patient and physician. Patients were diagnosed with 
moderate/severe lipodystrophy if they had 1 or more sites with a ‘severe’ score or 2 or more 
sites with a ‘moderate’ score. Patients were diagnosed with mild/moderate lipodystrophy if 
they had no signs of lipodystrophy or the signs were too mild for the moderate/severe group.  
Using the HOPS questionnaire, the HIV lipodystrophy case definition group developed the HIV 
lipodystrophy case definition (LDCD) score [99], and later developed the lipodystrophy 
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severity grading scale [100]. A case-control study design was used, and 1081 HIV-infected 
patients enrolled from sites in North America, Europe, Australia, Asia and South America. 
Questions on fat gain or fat loss in 8 areas were recorded (face, neck, dorso-cervical spine, 
arms, breast, abdomen, buttocks and legs). The degree of fat accumulation or fat loss at each 
site was rated as absent (score = 0), mild (score = 1), moderate (score = 2), or severe (score 
=3) [100]. A lipodystrophy grade was proposed based on the severity score; grade 0 (zero 
score), grade 1 (score of 1-6), grade 2 (score of 7-12), grade 3 (score of 13-18) and grade 4 
(score of >19) [100].  However, the HOPS and LDCD scores do not differentiate between 
lipoatrophy and lipohypertrophy.  
Results from studies comparing patient report to clinical examination have been 
contradictory as both high levels of agreement [101,102] and poor agreement [83,103,104] 
between these two methods have been reported. In addition, when using different severity 
score ratings, the prevalence was vastly different [75,83].  
Objective assessment methods 
Objectives measures used to diagnose lipodystrophy, lipoatrophy and lipohypertrophy in 
high-income countries include DXA, CT and MRI scans (Table 5). Lipoatrophy measured by 
DXA has been defined as ≥ 20% loss in limb fat [13,86,89,105-108], and at times as ≥ 10% loss 
in limb fat [89,109]. When measured by MRI, lipoatrophy was defined as leg SAT below the 
10th percentile [110], and when diagnosed by CT scan lipoatrophy was defined as a decrease 
in SAT [108,111,112].  
Lipohypertrophy measured by DXA has been defined as ≥ 20% gain in trunk fat [105,106], as 
well as a change in the percentage trunk fat [89]. When measured by CT scan, lipohypertrophy 
was defined as an increase in VAT   [89,111,112]. One study used MRI to measure change in 
VAT [110]. 
In an attempt to standardise measures of lipodystrophy, Bonnet et al. [113], developed an 
objective measure and defined standard values for defining lipodystrophy based on DXA. The 
authors used a cross sectional study design and 403 French men (241 HIV-uninfected; 34 HIV-
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infected ART-naïve; 128 HIV-infected on ART). Fat mass ratio (FMR), defined as the ratio of 
percentage trunk fat over the percentage lower limb fat, was proposed as an objective 
lipodystrophy measure. Lipodystrophy was defined as FMR ≥ 1.5. In 2010, Freitas et al. [114], 
using a population of HIV-infected Portuguese men and women on ART, proposed separate 
reference values for men and women (men: FMR ≥1.961; women: FMR ≥1.329). In 2012, Asha 
et al. [115] reported that a FMR of >2.28 identified 54.3% of HIV-infected Indian men on ART. 
However, Asha et al. defined FMR as the ratio of trunk fat mass in grams to lower limb fat 
mass in grams. 
To date studies reported from sub-Saharan Africa have not used objective measures such as 
DXA, MRI or CT scans to define lipodystrophy. As patient report and clinical examination are 
the most commonly used diagnostic methods in sub-Saharan Africa, and studies have shown 
poor correlation between the two methods, it emphasises the need for the development of 
an objective diagnostic tool.   
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Table 5. Objectives measures used for defining lipoatrophy, lipohypertrophy and lipodystrophy  







Canada [105] RCT 155 DXA ≥ 20% limb fat loss ≥ 20% trunk fat gain  
France [113] Cross 
sectional 
study 
403 DXA   FMR (ratio between % 
trunk fat and % lower 
limb fat) 
France [116] RCT 100 CT scan SAT VAT SAT:TAT ratio 
India [115] Cross 
sectional 
study 
105 DXA   FMR (ratio between 




RCT 48 DXA 
CT scan 
Limb fat (g)  
SAT 
VAT VAT:SAT ratio 
Multi-country 
[86] 
RCT 563 DXA ≥ 20% limb fat loss   
Multi-country 
[106] 
RCT 136 DXA ≥ 20% limb fat loss 
 
≥ 20% trunk fat gain  
Portugal [94] Cross 
sectional 
study 
345 DXA   FMR (ratio between % 
trunk fat and % lower 
limb fat) 
Spain [107] RCT 54 DXA ≥ 20% limb fat loss 




Spain [117] Cross 
sectional 
study 
168 DXA   FMR (ratio between 
trunk fat and lower 
limb fat) 
USA [109] RCT 334 DXA ≥ 10% limb fat loss    
USA [13] RCT 753 DXA ≥ 20% limb fat loss   
USA [108] RCT 200 DXA 
CT scan 
≥ 20% limb fat loss 
Limb fat (g) 
SAT 
Trunk fat (g) 
VAT 
 





Limb fat (g)   
USA [110] Longitudinal 691 MRI Leg SAT < 10th 
percentile 
VAT  
USA and Puerto 
Rico [89] 
RCT 269 DXA 
CT scan 
≥ 10% limb fat loss  
≥ 20% limb fat loss 
% change in limb fat 
% change in trunk fat 
% change in VAT 
 
 
USA [119] Cross 
sectional 
study 
66 DXA   FMR (ratio between 
trunk fat and lower 
limb fat) 
RCT – randomised control trial; DXA - Dual energy X-ray absorptiometry; CT – computerised tomography; MRI – magnetic resonance imaging; VAT – visceral adipose tissue; 
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Chapter 3. Methods 
Data for this thesis came from three datasets, collected between 2007 and 2013. All datasets 
consisted of black HIV-infected men and women presenting to ART clinics in Cape Town. The 
first dataset is a cross-sectional study, while the second and third datasets are longitudinal 
studies (Table 1). These three datasets form the Metabolic Complications of HAART 
(McHAART) study, and was aimed at determining the prevalence of metabolic complications 
in HIV-infected patients receiving ART. 
Table 1. Summary of thesis results chapters by data source, objective and publication title  
Chapter Dataset Objective Publication title 
4 Longitudinal 
dataset A 
To assess the effects of long-term 
antiretroviral exposure on blood 
pressure, glycaemia, insulin 
secretion and anthropometric 
measures in black South African 
women 
Changes in blood pressure, 
glucose levels, insulin secretion 
and anthropometry after long 
term exposure to antiretroviral 




To use DXA scans to describe the 
changes in fat distribution over a 
24 month period in a population 
of black South African men and 
women initiated on ART 
Changes in body fat distribution 
on dual-energy x-ray 
absorptiometry in black South 
Africans starting first-line 
antiretroviral therapy 
To investigate factors associated 
with changes in fat distribution 
6 Cross sectional 
dataset 
To develop simple, objective 
measures to define lipoatrophy 
and lipohypertrophy using patient 
report as the reference standard 
The development of simple 
anthropometric measures to 
diagnose antiretroviral therapy-
associated lipodystrophy in 
resource limited settings 
7 Longitudinal 
dataset B 
To use change in DXA measures to 
validate the newly developed 
measures of lipoatrophy and 
lipohypertrophy 
Anthropometric definitions for 
antiretroviral associated 
lipodystrophy derived from a 
longitudinal South African 







3.1 Ethical approval 
The McHAART study was approved by the Research Ethics Committee of the Faculty of Health 
Sciences at the University of Cape Town. All procedures and risks were explained to 
participants, after which written, informed consent to participate in the study was obtained. 
Participants provided additional consent for the storage of genetic samples and linkage with 
clinical data. 
3.2 Cross Sectional Study 
For the cross sectional study (Figure 1), HIV-infected patients were conveniently sampled 
from two Cape Town ART clinics between 2007 and 2009.  
Figure 1: Diagrammatic representation of the cross sectional study 
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Participants who were recruited included those who were ART-naïve, and those on either 
first-line ART treatment (consisting of stavudine or zidovudine, with lamivudine and either 
efavirenz or nevirapine) or second-line ART treatment (consisting of zidovudine with 
didanosine, and ritonavir-boosted lopinavir). Patients were excluded from recruitment based 
on a list of predefined conditions (Table 2). 
Table 2. Cross Sectional Study - recruitment exclusion criteria 
 Exclusion criteria 
1 On ART for less than 6 months 
2 Showing signs of acute opportunistic infections 
3 Experiencing severe diarrhoea (>6 stools per day) 
4 Diagnosed with tuberculosis within one month of starting treatment 
5 History of diabetes mellitus 
6 Received glucocorticoid therapy within the last six months 
7 Pregnancy  
8 Renal failure 
After the initial screening and enrolment into the study, participants were provided with an 
appointment date and instructed to fast the night before the appointment. On the day of the 
appointment, participants underwent a 75g oral glucose tolerance test (OGTT). Venous blood 
samples were taken at 0, 30 and 120 minutes. The samples were kept on ice and centrifuged 
within 4 hours, aliquoted and frozen at -20◦C, then stored at -70◦C until analysis at the end of 
the recruitment in 2009.  
An interviewer administered questionnaire was used to collect socio-demographic 
information, while a second interviewer administered questionnaire collected information on 
fat gain and fat loss for all participants. Anthropometric measurements were taken by a single 
anthropometrist. Weight, height, circumferences (waist, hip, mid-upper arm, and mid-thigh), 
skinfold thickness (biceps, triceps, subscapular, abdomen, supra-iliac, thigh and calf) and 
sagittal abdominal diameter (SAD)] were measured. A sub-sample of this group had a dual-






Three blood pressure (BP) measurements were taken at 2-minute intervals using an Omron 
BP monitor with an appropriately sized cuff after the participant had been seated for 5 
minutes. Patients’ clinical records from the health facility were reviewed to obtain data on 
ART regimen, time on ART, viral load and CD count. 
3.3 Longitudinal Study A 
The first longitudinal study (Figure 2), followed participants on first-line treatment, who were 
enrolled in the Cross Sectional Study, for a period of 4-6 years.  
 Figure 2. Diagrammatic representation of Longitudinal Study A 
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as they had moved, changed contact details or had died. Patients who were able to be 
contacted, underwent an initial screening and were excluded from the follow-up study based 
on a set of predefined criteria (Table 3). The same measurements as described in the cross 
sectional study were used, and data collected using the same procedures and measurement 
instruments.   
Table 3. Longitudinal Study A - recruitment exclusion criteria 
 Exclusion criteria 
1 Pregnancy  
2 Non-adherence to medication 
3 Showing signs of acute opportunistic infections 
4 Experiencing severe diarrhoea (>6 stools per day) 
5 Renal failure 
 
3.4 Longitudinal Study B 
For the second longitudinal study (Figure 3), newly diagnosed HIV-infected patients who were 
ART naïve when recruited, were followed for 24 months. Recruitment occurred between 2008 
and 2010. Data were collected at baseline, 3 months, 6 months, 12 months, 18 months and 
24 months. ART initiation occurred within one week of being diagnosed. In cases where 
initiation was delayed, participants were excluded from the study. Patients underwent an 












Table 4. Longitudinal Study B - recruitment exclusion criteria 
 Exclusion criteria 
1 Pregnancy  
2 Showing signs of acute opportunistic infections 
3 Experiencing severe diarrhoea (>6 stools per day) 
4 Diagnosed with tuberculosis within one month of starting treatment 
5 Renal failure 
 
The same measurements as described in the cross sectional study were collected using the 











 Oral glucose tolerance test 
 Cholesterol 
 Triglyceride  
 Blood pressure 
 Anthropometry 
 Fat gain and loss 
questionnaire 
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A number of metabolic abnormalities, such as dysglycaemia, insulin resistance, lipodystrophy 
and dyslipidaemia, are associated with the use of antiretroviral drugs. We aimed to assess the 
effects of long-term antiretroviral exposure on blood pressure, glycaemia, insulin secretion 
and anthropometric measures in black South African women. 
Methods 
A convenience sample of HIV-infected women on first-line ART for a median of 16 months at 
baseline, had the following evaluations twice, at baseline and after approximately 5 years: 
anthropometry, including skin fold thicknesses, blood pressure, oral glucose test, and insulin. 
Insulin sensitivity and secretion (HOMA-IR, IGI and DIo) were estimated. 
Results 
At baseline more than half the 103 women were using stavudine and efavirenz. The median 
interval between baseline and follow-up evaluation was 66 months. Weight, waist 
circumference, and waist-hip ratio increased over time, while limb skinfold thickness 
decreased over time. Systolic and diastolic blood pressure increased significantly and the 
proportion of participants with hypertension increased from 3.9% to 15.5% (p<0.001). There 
were increases from baseline in plasma glucose concentrations at 30 and 120 minutes; insulin 
concentrations at 0 and 30 minutes; and IGI and DIo. The proportion of participants with 
diabetes increased from 1% to 7.5% (p=0.070). 
Conclusion 
In women with long-term exposure to ART, increases in hypertension and possibly diabetes 
were observed. Participants experienced an increase in central fat and a decrease in 
peripheral fat distribution. Early identification and management of these metabolic changes 







Africa has made great strides in expanding access to antiretroviral therapy (ART), with an 
estimated 7.6 million people in sub-Saharan Africa receiving treatment by December 2012 
[1]. The increase in access to ART has resulted in a dramatic decline in HIV-related deaths. 
However, several antiretroviral drugs are associated with a number of metabolic 
abnormalities [2] including dyslipidaemia, lipodystrophy, insulin resistance and dysglycaemia 
[3]. 
Several studies from Africa have shown an increased prevalence of dysglycaemia in HIV-
infected patients, especially in patients on ART, but the duration of ART exposure was 
generally under 3 years [4-6]. There are conflicting data with regard to the impact of HIV and 
ART on hypertension, with some studies showing an increased risk of hypertension [7,8] and 
others showing no association [9-11]. A recent systematic review by Dillon et al. [12] found 
that HIV-infected patients in sub-Saharan Africa, irrespective of ART status, had lower systolic 
and diastolic blood pressure (BP) when compared to HIV-uninfected controls.   
ART-related lipoatrophy is common in low- and middle-income countries [13-15], where 
stavudine has only recently been phased out and zidovudine is still widely being used. Studies 
using anthropometric measures show that fat loss is best detected by triceps skinfold and hip 
circumference measurements [13,16]. Central fat accumulation in patients on ART is thought 
to be a consequence of treating the HIV infection, as the gain in trunk and visceral fat is no 
different between HIV-infected participants on ART and  HIV-uninfected controls, and does 
not differ by antiretroviral class [17].   
Little is known about the long-term metabolic effects of ART in low- and middle-income 
countries. We aimed to assess the effects of long-term ART exposure on blood pressure, 








In our initial cross sectional study, undertaken in 2007-2009 to examine the metabolic 
consequences of ART, a convenience sample of 345 HIV-infected black African women on 
first-line ART who were being followed up at ART clinics in Cape Town were selected. The 
recruitment procedure is described elsewhere [5]. At that stage the first-line ART regimen 
consisted of stavudine, lamivudine or zidovudine and efavirenz or nevirapine, and the second-
line ART regimen consisted of zidovudine with didanosine and lopinavir/ritonavir [18]. 
Subsequently, the first-line regimen was changed to tenofovir and efavirenz or nevirapine, 
and lamivudine replaced didanosine in the second-line regimen. NRTI drug substitutions for 
toxicity or the convenience of a fixed dose combination are not considered switches to 2nd 
line ART. 103 of the initial 345 participants could be traced approximately 5 years later and 
underwent repeated assessments. The remainder could not be traced using their home 
address or telephone number and were no longer attending the health facility from which 
they were recruited; defaulted, were pregnant or had died.  The baseline characteristics did 
not differ between those we traced and those not traced. 
Testing procedures 
We used the same procedures to collect information from participants at baseline and follow-
up. Socio-demographic information was collected using an interviewer administered 
questionnaire. Clinical records were obtained from health facilities and reviewed to obtain 
data on ART regimen, time on ART and CD4 count. The Lipodystrophy Case Definition (LDCD) 
questionnaire [19] was used to collect self-reported information on fat gain or fat loss. Self-
reported lipoatrophy was defined as in the HIV Outpatient Study (HOPS), as moderate or 
severe fat loss in 2 or more regions and self-reported lipohypertrophy defined as moderate 






After an overnight fast, participants underwent a 75g oral glucose tolerance test (OGTT). 
Venous blood samples were taken prior to glucose ingestion, and after 30 and 120 minutes. 
The plasma was stored and analysed as previously described [5].  
Anthropometric measurements: [weight, height, circumferences (waist, hip, mid-upper arm, 
and mid-thigh), skinfold thickness (biceps, triceps, subscapular, abdomen, supra-iliac, thigh 
and calf) and sagittal abdominal diameter (SAD)] were also done.  Cut-point based lipoatrophy 
was defined as having a thigh skinfold thickness ≤28 mm or a triceps skinfold thickness of 
≤14.5 mm [13]. Three BP measurements were taken at two-minute intervals using an Omron 
BP monitor with an appropriately sized cuff after the participant had been seated for five 
minutes. The average of the second and third BP measurements was used in the analyses. 
Hypertension was defined as BP ≥140/90 mmHg or using antihypertensive agents. Diabetes, 
IGT and IFG were defined using the American Diabetes Association criteria [21].  
Ethical Approval 
The study proposal was submitted and approved by the Research Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town. Written informed consent was 
obtained from all participants prior to participation in the study. 
Data Analyses 
Data analysis was carried out using the STATA/SE statistical software package version 12.0 
(StataCorp., College Station, TX, USA). Baseline data were collected between February 2007 
and June 2009 and follow-up data between July 2011 and July 2013. Because the data were 
not normally distributed, continuous variables were described as medians and inter-quartile 
ranges (IQR), and were compared using a non-parametric paired t-test. Binary variables were 
described using numbers and percentages, and compared using the McNemar chi-square test 
for paired data.  
Markers of beta cell function and insulin resistance were estimated in the participants who 






as the ratio of the change in insulin to the change in glucose from 0 to 30 min (ΔInsulin0-
30/ΔGlucose0-30), and (2) DIo, calculated as a (ΔInsulin0-30/ΔGlucose0-30) x (1/fasting insulin). 
Insulin resistance was estimated using HOMA-IR, calculated as (fasting glucose x fasting 
insulin)/22.5. 
4.4 Results 
Participant characteristics are presented in Table 1. We enrolled 103 of the 345 women 
assessed at baseline for follow-up assessment. At baseline the participants had spent a 
median of 16 months on first-line ART and almost all were using stavudine (91%) and 
lamivudine (100%). At follow-up 84% were still on first-line ART but the percentage of those 
using stavudine had decreased to 39%, and those using zidovudine had increased from 10% 
to 38%. The median time on ART at follow-up was 82 months (6.8 years). 
As shown in Table 2, waist circumferences increased significantly (p=0.038), while hip and 
mid-thigh circumferences decreased (p<0.001). All skinfold thicknesses changed significantly 
from baseline to follow-up. All 25% of the participants who reported having lipoatrophy at 
baseline, reported none at follow-up. However, when using objective measures [13] based on 
thigh and triceps cut-points, the percentage of participants with lipoatrophy increased from 
44% to 64%; p=0.010. At baseline, 60% of those who self-reported moderate or severe fat 
loss in 2 or more regions, were correctly classified using thigh and triceps skinfold cut-points, 















Age 33.5 [30.0-40.0] 40.1 [35.7-45.4] 
Current CD4 count 3723 [261-471] 564 [427-774] 
Time on ART (months) 16.0 [10.0-26.0] 82.4 [73.8-94.1] 
 
n[%] n[%] 
Education   
No schooling 5 [4.8]  
Primary School 14 [13.6]  
Secondary School 83 [80.6]  
Tertiary 1 [1.0]  
Drug Regimen   
1st line ART 84 [100] 65 [84.4] 
2nd line ART 0 [0] 12 [15.6] 
ART   
Stavudine 76 [90.5] 30 [39.0] 
Lamivudine 84 [100] 77 [100] 
Zidovudine 8 [9.5] 29 [37.7] 
Tenofovir 0 [0.0] 18 [23.4] 
 Lopinavir 0 [0.0] 12 [15.6] 
 Efavirenz 41 [48.8] 36 [46.8] 
 Nevirapine 43 [51.2] 29 [37.7] 
 
Both systolic and diastolic blood pressures increased (p<0.001) from baseline to follow-up 
(Table 3). Plasma glucose concentrations at 30 and 120 minutes, and  insulin concentrations 
at 0 and 30 minutes also increased significantly from baseline to follow-up (p<0.050). 
Although the homeostatic assessment model (HOMA-IR) tended to increase (p=0.089) from 
baseline to follow-up, both the insulinogenic index (IGI) and the oral disposition index (DIo) 















Height (m) 1.6 [1.5-1.6] 1.6 [1.5-1.6] 0.401 
Weight (kg) 69.2 [61.4-81.1] 70.1 [59.7-78.8] 0.402 
BMI 27.9 [24.8-31.8] 27.8 [23.9-31.6] 0.443 
Sagittal height (cm) 21 [19-24] 20.6 [18.5-23.5] 0.640 
Circumferences 
Waist (cm) 89.8 [81.3-96.8] 90.8 [82.5-100.0] 0.038 
Hip (cm) 103.0 [96.0-114.0] 100.0 [91.8-106.5] <0.001 
Waist-hip ratio 0.86 [0.81-0.92] 0.92 [0.85-0.98] <0.001 
Mid-upper arm (cm) 29.0 [27.0-32.0] 29.5 [26.8-32.5] 0.292 
Mid-thigh (cm) 58.0 [53.0-63.0] 55.0 [49.5-59.5] <0.001 
Skinfold thickness 
Biceps (mm) 8.1 [5.8-10.5] 9.0 [6.4-12.6] 0.011 
Triceps (mm) 19.0 [12.6-25.2] 16.3 [11.3-22.5] 0.007 
Abdomen (mm) 25.1 [16.9-34.2] 32.2 [21.7-37.8] <0.001 
Thigh (mm) 32.8 [24.1-43.3] 24.3 [17.3-34.0] <0.001 
Sub-Scapular (mm) 21.5 [13.4-28.8] 29.0 [18.8-34.2] <0.001 
Supra-iliac (mm) 16.1 [9.9-22.4] 20.5 [13.3-28.9] <0.001 
Calf (mm) 17.8 [12.3-24.4] 13.1 [7.0-19.2] <0.001 
        
n[%] n[%] P-value** 
Lipoatrophy 
      Based on Patient Report 25 [24.5] 0 <0.001 
      Based on thigh (≤28 mm) and 
triceps (≤14.5 mm) skinfold 
cut-points  
45 [43.7] 59 [64.1] 0.010 
*non-parametric paired t-test 
**McNemar Chi-square test for paired data 
The proportion of participants with hypertension increased from baseline to follow-up, from 
3.9% to 15.5%; p<0.001 (Table 4). While the proportion of participants with impaired glucose 
tolerance (IGT), impaired fasting glucose (IFG) and dysglycaemia did not change significantly 
from baseline to follow-up, there was a trend to an increase in the proportion of participants 
with diabetes (1% to 7.5%; p=0.070). At baseline and follow-up, diabetes, hypertension and 
dysglycaemia were significantly associated with lipoatrophy (p<0.001) based on thigh and 






Table 3. Comparison of blood pressure, plasma glucose and insulin concentrations and markers 
of insulin sensitivity and beta cell function at baseline and follow-up (n=103) 






Systolic 111 [101-121] 121 [112-133] <0.001 
Diastolic 72 [64-80] 80 [73-89] <0.001 
Glucose 
Fasting 5.1 [4.7-5.4] 4.9 [4.7-5.3] 0.365 
30 mins 6.6 [5.8-7.4] 6.8 [5.9-8.0] 0.040 
120 mins 5.4 [4.9-6.3] 5.6 [4.7-6.8] 0.028 
Insulin 
Fasting 5.6 [3.3-9.5] 7.9 [4.1-12.9] 0.009 
30 mins  35.1 [19.2-66.7] 177.7 [163.4-192.5] <0.001 
120 mins 24.0 [13.5-40.2] 23.7 [10.4-54.9] 0.993 
Glycaemic parameters (without diabetics and outliers) 
HOMA-IR** 1.2 [0.7-2.2] 1.6 [0.9-2.7] 0.089 
IGI*** 23.7 [11.9-33.1] 80.0 [54.0-137.4] <0.001 
DIo**** 3.5 [2.3-7.9] 11.9 [4.9-23.3] <0.001 
*non-parametric paired t-test 
**HOMA-IR= (fasting glucose x fasting insulin)/22.5 
***IGI= ΔInsulin0-30/ΔGlucose0-30   
****DIo [Oral disposition index] = (ΔInsulin0-30/ΔGlucose0-30) x (1/fasting insulin) 
 








Hypertension 3 [3.9] 16 [15.5] <0.001 
Glucose abnormalities**    
      Diabetes 1 [1.0] 7 [7.5] 0.070 
      Impaired Glucose Tolerance 6 [5.8] 9 [9.6] 0.344 
      Impaired fasting Glucose 17 [16.5] 10 [10.5] 0.308 
      Dysglycaemia 22 [21.4] 19 [20] 1.00 
*McNemar Chi-square test for paired data 







Stavudine, efavirenz and nevirapine were significantly associated with diabetes, hypertension 
and dysglycaemia at follow-up (Table 5). Lipoatrophy was significantly associated (p<0.001) 
with zidovudine, tenofovir, lopinavir in addition to stavudine, efavirenz and nevirapine. 
Table 5. P-values* representing associations between diabetes, hypertension, dysglycaemia and 
lipoatrophy, and different antiretroviral drugs at follow-up 
 Diabetes Hypertension Dysglycaemia Lipoatrophy** 
Stavudine 0.001 0.017 0.029 <0.001 
Zidovudine 0.031 1 0.845 <0.001 
Tenofovir 0.004 0.690 0.856 <0.001 
Lopinavir 0.077 0.664 0.690 <0.001 
Efavirenz 0.001 <0.001 <0.001 <0.001 
Nevirapine <0.001 0.029 0.029 <0.001 
*McNemar Chi-square test for paired data 
**Defined by thigh and triceps skinfold cut-points 
 
4.5 Discussion 
Our results show that long term exposure to ART in South African women is associated with 
increases in blood pressure, glucose and insulin levels. These women also experienced 
changes in body composition with a significant increase in the waist-hip ratio, and in the 
prevalence of lipoatrophy when objective anthropometric measures (thigh and triceps 
skinfold cut-points [13]) were used instead of the subjective measure of patient report. These 
metabolic and body composition changes are all associated with an increased cardiovascular 
risk [22].  
The prevalence of hypertension at baseline in our study was 3-fold lower than in women of a 
similar age-group from a similar area in Cape Town who participated in a community-based 
cardiovascular risk factor study (CRIBSA). At follow-up the prevalence of hypertension was 






was not performed in the CRIBSA Study, participants were not known to be on ART and based 
on local data, the HIV-infected proportion was estimated to be about 10% [23]. Another study 
from rural KwaZulu Natal, South Africa [24] reported a 20% prevalence of hypertension in 
HIV-infected women compared to 40% in HIV-uninfected women 15 years and older. The 
lower BMI in people on ART compared to the HIV negative participants may be an explanation 
for the lower prevalence of hypertension in both of these South African studies. In contrast, 
studies from Tanzania [7] and Uganda [7,25] have reported a similar prevalence of 
hypertension in HIV-infected and HIV-uninfected participants, with those on ART in Tanzania 
having a higher BMI than those who were HIV-uninfected or HIV-infected and ART-naive.  
Although the prevalence of new onset diabetes increased between baseline and follow-up in 
our study, this did not reach statistical significance, possibly due to the small sample size. 
Interestingly, the prevalence of new onset diabetes at follow-up, was 2-fold higher in our 
study than the prevalence of new onset diabetes in women of similar ages from the CRIBSA 
study [23]. The different methods used to assess dysglycaemia makes it difficult to compare 
studies from Africa. However, a study [26] that also used an OGTT to assess dysglycaemia 
found a similar prevalence of dysglycaemia, although the length of time on ART was longer in 
our study (81 months vs. 48 weeks). The rise in insulin secretion in relation to insulin 
resistance, as expressed by the DIo, in the majority of the group at follow-up explains their 
lack of development of diabetes.  
Although there was no increase in BMI at follow-up, the greater abdominal skinfold thickness 
and waist-hip ratio together with peripheral wasting suggests a marked difference in body 
composition with centralisation of body fat, in agreement with a number of other African 
studies [5,13,16,27]. HIV-associated central fat accumulation likely reflects the consequence 
of treating the HIV infection rather than a specific antiretroviral adverse drug reaction [17]. 
We found an increase in the percentage of participants with lipoatrophy when defined by 
thigh and triceps skinfold cut-points [13]. However, when using patient report to diagnose 
lipoatrophy, no women had lipoatrophy, including the 25% who reported lipoatrophy at 
baseline. The discrepancy we found in the proportion of women with lipoatrophy on 






their new body shape and illustrates the limitations of diagnosing lipodystrophy using a 
subjective measure. Lipoatrophy is an antiretroviral adverse drug reaction, strongly 
associated with the use of thymidine analogue nucleoside reverse transcriptase inhibitors 
(NRTIs), stavudine and zidovudine [17]. In our study more than 30% of women were still on 
stavudine at follow-up and almost 20% were still taking zidovudine. The baseline prevalence 
of lipoatrophy we found is also similar to that of another South African study [16], which 
reported a 43% prevalence after two years of treatment, but they defined lipoatrophy only 
by subjective patient and healthcare worker reports. 
Our study has some limitations. The lack of HIV-uninfected and ART-naïve control groups 
limits our ability to attribute the changes observed to the use of ART. The sample size was 
also relatively small, which limited our ability to assess whether the increased prevalence of 
diabetes over time was significant. Despite these limitations, ours is one of very few studies 
in Africa to use an OGTT to define dysglycaemia and to follow women on ART for over 5 years.   
4.6 Conclusion 
In this study from Africa we showed that long-term use of ART results in an increase in blood 
pressure (systolic and diastolic), the prevalence of hypertension and possibly diabetes. The 
greatest changes observed were in body composition, with an increase in central fat and a 
decrease in subcutaneous fat. The prevalence of lipoatrophy, when defined by skinfold cut-
points, increased substantially. These findings have important implications for the 
management of HIV in Africa. The early identification and management of these 
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Changes in body fat distribution on dual-energy x-ray absorptiometry 
in black South Africans starting first-line antiretroviral therapy 
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Long term use of antiretroviral therapy (ART) increases the risk of developing lipodystrophy. 
No studies from Africa have used longitudinal data to assess the development of lipoatrophy 
and lipohypertrophy. We use clinical anthropometry and dual-energy X-ray absorptiometry 
(DXA) to describe changes in body fat distribution over a 24 month period in individuals 
initiated on ART. 
Methods 
A convenience sample of black South African men and women were recruited from 
Community Healthcare Centres and followed for 24 months after commencing ART. Body fat 
distribution was assessed using anthropometric measurements and DXA scans at baseline and 
then at 3 months, 6 months, 12 months, 18 months, and 24 months after commencing ART. 
DXA was also used to estimate abdominal visceral adipose tissue (VAT) and subcutaneous 
adipose tissue (SAT). Clinical records were reviewed to obtain information on ART regimens, 
viral loads and CD4 counts. 
Results 
Women gained more overall weight and more regional fat in all areas analysed on DXA scans. 
Women, not men, experienced a significant increasing trend in trunk fat and a significant 
decreasing trend in limb fat, when expressed as a percentage of total body fat. In men, the 
risk of developing lipoatrophy was 2.85 times greater than women, after adjusting for age, 
baseline BMI and ART regimen. Lipohypertrophy occurred similarly in men and women.  VAT 
and SAT increased significantly in men and women, with women gaining considerably more 







Using clinical anthropometry and DXA we describe distinct differences in body fat distribution 
in men and women after initiating ART.  These findings are of great concern as an increased 
waist circumference is associated with increased mortality in HIV-infected populations. 
Further investigation is required to understand the mechanisms underlying the sex 
differences in changes in body fat distribution and its effects on cardiovascular risk. 
5.2 Introduction  
Since the introduction of antiretroviral therapy (ART), HIV-related deaths have dramatically 
decreased [1]. However, the long-term use of ART increases the risk of metabolic 
complications such as lipodystrophy, insulin resistance, dyslipidaemia and lactic acidosis.  
Lipodystrophy, in the form of lipoatrophy and/or lipohypertrophy, occurs with differing 
frequency and severity in patients using ART. The need to differentiate between lipoatrophy 
and lipohypertrophy has become imperative following a recent meta-analysis showing that 
lipoatrophy, but not lipohypertrophy, is an antiretroviral adverse drug reaction [2]. 
Lipodystrophy especially lipoatrophy, has been commonly reported in studies from Africa 
when using stavudine and zidovudine [3-6]. 
Subjective methods such as patient report [4,7,8] and objective methods, such as dual energy 
X-ray absorptiometry (DXA) [9,10], computerised tomography (CT) and magnetic resonance 
imaging (MRI), have been used to detect lipoatrophy and lipohypertrophy [2]. However, few 
studies from Africa have distinguished between lipoatrophy and lipohypertrophy [3,4,11], 
and none have used changes in DXA measures. Longitudinal studies using DXA measures to 
define lipoatrophy and lipohypertrophy have frequently been done in high-income countries 
[10,12] and have shown that  lipoatrophy occurs more frequently in patients using a 
stavudine-based ART regimen. However, subjects in these studies were mostly middle-age 







The aim of our study was to use DXA scans to describe the changes in fat distribution over a 
24 month period in a population of black South African men and women initiated on ART and, 
to investigate the factors associated with these changes.  
5.3 Methods 
Participants 
A convenience sample of HIV-infected men and women presenting at Crossroads Community 
Health Centre in Cape Town were enrolled in a 24 month longitudinal study. A sample size 
calculation based on a population of 500, 5% margin for error, and 95% confidence interval, 
indicated that a sample size of 184 participants was needed. ART initiation occurred after 
enrolment into the study and completion of baseline evaluations. During the course of the 
study there was a change in the nucleoside reverse transcriptase inhibitors (NRTIs) used in 
first-line ART regimens in South Africa, from stavudine or zidovudine to tenofovir, together 
with lamivudine, and efavirenz or nevirapine. The second-line regimen consisted of 
zidovudine, didanosine and lopinavir/ritonavir, which was changed to zidovudine, lamivudine 
and lopinavir/ritonavir at the same time as the tenofovir change [13].  
Testing procedures 
An interviewer administered questionnaire was used to collect socio-demographic 
information from participants at the beginning of the study. Anthropometry (weight and 
height) and dual-energy X-ray absorptiometry (DXA) was performed at baseline, 3 months, 6 
months, 12 months, 18 months, and 24 months. DXA (Discovery-W®, software version 
12.7.3.7; Hologic, Bedford, MA) was used to measure fat mass according to standard 
procedures. DXA cut-off lines positioned at anatomical markers were used to obtain fat mass 
for the whole body as well as for the various regions of interest (arms, legs and trunk). The 
trunk comprised the region between the neck and waist, excluding the arms. Limb 
composition was determined by summing the arms and legs. The percentages for regions 
were calculated as a proportion of the whole body fat mass. A more detailed description has 






adipose tissue (SAT) areas were estimated by a trained analyst using image analysis software 
(SliceOmatic V4.2, TomoVision, Montreal, Quebec, Canada). The DXA measure of VAT has 
been shown to perform as well as VAT measured using computerized tomography scans [15].  
Clinical records obtained from health facilities were reviewed to obtain information on ART 
regimens, viral loads and CD4 counts. 
Ethical approval 
The study proposal was approved by the Research Ethics Committee of the Faculty of Health 
Sciences at the University of Cape Town. Written informed consent was obtained from all 
participants prior to participation in the study. 
Data analysis 
Data analysis was carried out using the STATA/SE statistical software package version 12.0 
(StataCorp., College Station, TX, USA). Baseline measurements were collected between 
November 2008 and November 2010. Because the data were not normally distributed, 
continuous variables were described as medians and inter-quartile ranges (IQR), and were 
compared using Wilcoxon Rank Sum tests. Binary variables were described using frequency 
and percentages, and compared using chi-square tests. The Jonckheere-Terpstra test for 
ordered variables was used to measure trends over time.  
Lipoatrophy was defined as (1) ≥ 20% loss of limb fat (all limbs combined) from baseline [10] 
and, (2) ≥ 10% loss of limb fat (all limbs combined) from baseline by DXA scan [16]. 
Lipohypertrophy was defined as ≥20% gain in trunk fat from baseline by DXA scan [17,18]. 
Differences in time to lipoatrophy and lipohypertrophy between men and women were 
calculated using the Kaplan-Meier method. The log rank test was used to test differences 
between groups. Cox proportional hazards regression modelling was used to analyse the 
contribution of the following variables, selected a priori: age, gender, BMI, and individual 
NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs), to the development of 
lipoatrophy. The Cox proportional hazards assumption was not met for lipohypertrophy, 






lipoatrophy model. Latent class mixed effects models are used to estimate mean longitudinal 
trajectories in potentially heterogeneous populations, by assigning a model of latent factors 
that determines class membership. The number of classes were set a priori and class 
membership was estimated by posterior probabilities. Latent class mixed effects models were 
fit to longitudinal data for limb fat and trunk fat change independently, with the same set of 
covariates as prior regression models. Two and three class models were fit and the final model 
chosen by best Aikaike Information Criterion (AIC). Posterior probabilities were estimated and 
latent classes characterised by summary statistics. 
5.4 Results 
Baseline characteristics of participants are shown in Table 1. The study sample consisted of 
55 (29.4%) men and 132 (70.6%) women who were ART naïve. Men were significantly older 
than women (35 vs. 31 years; p=0.008). Significantly more women than men were obese (20% 
vs. 4%; p=0.005).  After baseline measurements were collected, 25 participants (13.3%) were 
excluded from further participation in the study as they either did not meet the eligibility 
criteria for ART initiation or their ART initiation had been delayed. The number lost-to-follow-
up increased from 25 to 57 (30.5%) participants at 12 months and 84 participants (44%) at 24 
months on ART.  
More men (71%) than women (56%) were initiated on a stavudine-based regimen. After 12 
months on ART the proportion of participants on stavudine and tenofovir was no different 
than at baseline. However, after 24 months on ART, the proportion of participants on a 
stavudine-based regimen had decreased and those on a tenofovir-based regimen had 
increased. Only 1 participant was exposed to a drug regimen containing a protease inhibitor. 
After 6 months on antiretroviral therapy 73% of participants were virally suppressed (VL<50). 
Change in weight, BMI and regional DXA fat measures in men and women over the 24 month 
follow-up period can be found in Figure 1. In women, the total limb and trunk fat increased 
(P<0.001), while limb fat as a percentage of whole body fat decreased (P<0.001), primarily as 






7.6 kg to 11.7 kg (p<0.001).  In men, none of the regional changes in fat distribution were 
significant other than trunk fat, which increased from 3.65 kg to 4.16 kg (p=0.027). An increase 
in the derived variables of abdominal SAT and VAT were observed in both men and women 
(p<0.05). 











Age (years) 33.0 [27.0-39.0] 31.0 [26.0-38.0] 35.0 [29.0-41.0] 0.008 
CD4 156 [110-196] 161 [110-204] 137 [112-183] 0.126 
 n [%] n [%] n [%]  
Smoker 60 [32.3] 24 [18.3] 36 [65.5] <0.001 
BMI status (kg/m2)     
Underweight (BMI≤18.5) 10 [5.4] 4 [3.0] 6 [10.9] <0.001 
Normal weight (BMI 18.6-24.9) 108 [57.8] 66 [50.0] 42 [76.4]  
Overweight (BMI 25-29.9) 41 [21.9] 36 [27.3] 5 [9.1]  
Obese (BMI≥30) 28 [15.0] 26 [19.7] 2 [3.6]  
Antiretroviral drugs     
NRTI     
Stavudine 110 [60.8] 71 [56.4] 39 [70.9] 0.065 
Zidovudine 20 [11.1] 19 [15.1] 1 [1.8] 0.009 
Tenofovir 51 [28.2] 36 [28.6] 15 [27.3] 0.858 
NNRTI           
Efavirenz 66 [36.5] 38 [30.2] 28 [50.9] 0.008 
Nevirapine 115 [63.5] 88 [69.8] 27 [49.1] 0.008 
 
Kaplan-Meier plots of time to lipoatrophy and lipohypertrophy in men and women are shown 
in Figure 2. Lipoatrophy was observed in 20 of the 161 participants and occurred more 
frequently in men than in women (20% vs. 9.4%; p=0.066) but this difference was only 
significant when lipoatrophy was defined as ≥ 10% loss in limb fat (42.2% vs. 22.2%; p=0.011). 
Lipohypertrophy was observed in 90 of the 161 participants (55.9%), and was similar in men 
and women. Time to development of lipoatrophy and lipohypertrophy was not significantly 






Figure 1. Body composition changes (weight, BMI, DXA measures) in men and women over 24 months 
A: Weight (kg) 
Men p=0.009; Women p<0.001  
 
B: BMI 
Men p=0.002; Women p<0.001 
 
C: Limb fat (kg) 
Men p=0.211; Women p<0.001  
 
D: Limb fat (% of body fat) 
Men p=0.248; Women p<0.001  
 
E: Trunk fat (kg) 
Men p=0.027; Women p<0.001 
 
F: Trunk fat (% of body fat) 
Men p=0.085; Women p<0.001 
 
G: Abdominal Subcutaneous Adipose 
Tissue (kg) Men p=O.049; Women 
p<0.001 
 
H: Abdominal Visceral Adipose Tissue 
(kg) 







































































































Figure 2. Kaplan Meier curves of time to lipoatrophy and lipohypertrophy in men and women 
A: Lipoatrophy (limb fat loss ≥20%) P=0.089 
 
B: Lipoatrophy (limb fat loss ≥10%) P=0.006 
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Men have a greater than two times increased risk of developing lipoatrophy [HR=2.85 (0.96-
8.47); p=0.060] than women (Table 2), after adjusting for age, baseline BMI and ART regimen. 
The risk of developing lipohypertrophy (Table 3) did not differ by gender but showed a large 
effect [OR=0.59 (0.23-1.52); p=0.271], though not statistically significant. None of the 
antiretroviral drugs were significantly associated with lipoatrophy or lipohypertrophy. 
Table 2. Hazard Ratios for developing lipoatrophy using Cox regression modelling 
Parameter 
Univariate model Full multivariate model 
HR* (95% CI) 
p-value HR* (95% CI) p-value 
Age 0.98 (0.93-1.04) 0.505 0.97 (0.92-1.10) 0.352 
Gender (ref. female) 2.11 (0.87-5.09) 0.097 2.85 (0.96-8.47) 0.060 
BMI 0.97 (0.89-1.06) 0.462 1.03 (0.90-1.18) 0.665 
NRTI1: AZT (ref. d4T) 0.81 (0.19-3.50) 0.774 0.67 (0.88-5.07) 0.697 
NRTI2: TDF (ref. d4T) 0.55 (0.18-1.66) 0.287 0.50 (0.16-1.55) 0.227 
NNRTI: EFV (ref. NVP) 0.87 (0.33-2.29) 0.778 0.81 (0.30-2.21) 0.686 
*Hazard ratio; AZT-zidovudine; d4T-stavudine; TDF-tenofovir; EVF-efavirenz; NVP-nevirapine 
 
Table 3. Odds ratios for developing lipohypertrophy using logistic regression modelling 
Parameter 
Univariate model Full multivariate model 
OR* (95% CI) p-value OR* (95% CI) p-value 
Age 0.99 (0.96-1.03) 0.842 1.02 (0.97-1.07) 0.335 
Gender (ref. female) 0.98 (0.49-1.96) 0.956 0.59 (0.23-1.52) 0.271 
BMI 0.91 (0.85-0.97) 0.004 0.92 (0.83-1.03) 0.156 
NRTI1: AZT (ref. d4T) 0.57 (0.21-1.52) 0.259 1.50 (0.33-6.90) 0.605 
NRTI2: TDF (ref. d4T) 0.63 (0.32-1.25) 0.186 0.72 (0.30-1.73) 0.467 
NNRTI: EFV (ref. NVP) 1.17 (0.61-2.24) 0.644 0.76 (0.32-1.81) 0.537 
Time on ART (months) 0.995 (0.994-0.997) <0.001 0.99 (0.99-1.00) <0.001 






Latent class modelling was used to show limb fat and trunk fat change over time for each 
individual (Figure 3 and Table 4). The mean posterior of class membership in the limb fat 
model was class 1 = 0.91, class 2 = 0.89 and class 3 = 0.85. The mean posterior probability 
for class membership in the trunk fat model was class 1 = 0.91, class 2 = 0.94 and class 3 = 
0.82. For both limb fat and trunk fat, class 2 showed an increase over time. 
 
Figure 3. Limb fat (A) and trunk fat (B) longitudinal profiles for each individual where colour 
corresponds to estimate latent class membership based on posterior probabilities. Latent class 
labels (1, 2, 3) are arbitrary and merely reflect the group membership of each individual under a 
3-group latent class model 
A: Limb fat 
 
 









Table 4. Characteristics of classes as determined by latent class models for change in limb fat 
and trunk fat 
Parameter Class 1 Class 2 Class 3 
Limb fat 
Number of individuals (n=174) 124 13 37 
Baseline age (years) 33 30 31 
Women (n [%]) 76 [61.3] 13 [100] 34 [91.9] 
Baseline weight (kg) 59.1 63.0 73.5 
Baseline BMI (kg/m2) 21.6 25.0 28.6 
Trunk fat  
Number of individuals (n=174) 131 14 29 
Baseline age (years) 33 31 34 
Women (n [%]) 82 [62.6] 14 [100] 27 [93.1] 
Baseline weight (kg) 60.5 62.8 68.6 
Baseline BMI 22.1 25.2 26.8 
 
5.5 Discussion 
This is the first longitudinal study from sub-Saharan Africa to document changes in body 
composition using DXA in patients starting ART. Following the initiation of ART we observed 
striking gender differences in weight gain, with women gaining more overall weight and more 
regional fat in all areas analysed on DXA scans. Women, but not men, had a significant 
decrease in limb fat expressed as a percentage of total body fat, and a significant increase in 
trunk fat percentage, which are markers of lipoatrophy and lipohypertrophy, respectively. 
The incidence of lipoatrophy expressed as a categorical variable was higher in men than 
women. The incidence of lipohypertrophy, when expressed as a categorical variable, occurred 
similarly in men and women. The derived variables, abdominal VAT and SAT, increased 







We found that men had a 2.85 times greater risk of developing lipoatrophy than women, and 
that lipoatrophy occurred more frequently in men. This data is supported by other studies 
[10,19,20], however, the data is conflicting as there are also studies showing the risk in 
women to be greater than in men [3,11], while others found the risk to be similar by gender 
[21].  The greater risk in men in our study may be due to their lower baseline BMI as well as 
having less body fat, especially in the limbs, compared to women. In addition, more men than 
women were using stavudine at baseline, even though the difference was not statistically 
significant. Epidemiological studies from South Africa show that in the general population, a 
smaller proportion of black men are overweight or obese compared to black women (38.5% 
vs. 64.8%) [22]. Our study showed that after 24 months on ART, 12% of all participants 
developed lipoatrophy when defined by ≥ 20% loss of limb fat, and this increased to 28% 
when defined as ≥ 10% limb fat loss. This is lower than the findings in a large multi-centre 
randomised control trial [10] that showed a 32% occurrence when defined by ≥ 20% limb fat 
loss and 40% when defined by ≥ 10% limb fat loss. The difference may be explained in part by 
the majority of male subjects in the multi-centre trial versus the majority of women in our 
study. 
In 2003, the Lipodystrophy Italian Multicentre Study (LIMS) [21] reported different changes 
in fat distribution in men and women on ART, with women being more likely to develop fat 
accumulation around the abdomen. Similarly in 2009, McComsey et al. [23], found that 
women had a greater increase in trunk fat, SAT, VAT and TAT when compared to men.  
A systematic review by De Waal et al. [2] found that lipohypertrophy was not an adverse drug 
reaction, but appeared rather to be a consequence of treating the HIV infection, which 
reduces the inflammatory response that causes wasting. Our finding that lipohypertrophy 
occurred with similar frequency in men and women irrespective of drug regimen is in keeping 
with the findings of the systematic review. By contrast, the systematic review found good 
evidence that lipoatrophy is an adverse drug reaction, due largely to thymidine analogue 
nucleoside reverse transcriptase inhibitors, especially stavudine. We showed that the 






numerous studies [3,24,25], but the difference was not statistically significant, likely due to 
our small sample size.  
We also showed that over the 24 month period, weight and BMI increased significantly in 
both men and women. Interestingly, almost half of all women were either overweight or 
obese at the beginning of the study, when the criteria for ART eligibility was a CD4 count of 
<200 cells/mm3.  Furthermore, their median BMI increased from 24.8 kg/m2 to 27.7 kg/m2, 
and their median VAT increased by 190g during the two years. However, when using latent 
class analysis, we found a heterogeneous group within the sample, with the majority of 
individuals experiencing a longitudinal trajectory of limited, to no weight change over time. A 
minority of individuals, as supported by the other analyses, experienced longitudinal 
trajectories characterised by significant weight change, indicating that a minority of 
participants were responsible for the significant change in median weight and BMI. Our 
findings of increased weight and BMI mirror those of another South African study [26] 
showing that the BMI in HIV-infected women increased from 25 kg/m2 to 27.4 kg/m2 during 
the first year on ART. While the increase in weight and BMI may be due to a return to health 
in both men and women, a combination of mismatched weight perception and a cultural 
belief that underweight is associated with HIV infection may contribute to the increasing 
number of HIV-infected overweight and obese women. Studies on weight perception in HIV-
infected women [26,27] reported a mismatch between actual weight and weight perception, 
with a tendency for women to judge themselves as less than their actual weight. In South 
Africa, HIV-infected women continue to experience discrimination, which may be the cause 
of intentional obesity as a mechanism of limiting the stigma [28]. These findings are of great 
concern as an increased waist circumference, and especially increase in VAT, is associated 
with increased mortality in HIV-infected populations [29].  
Our study has some limitations. This was a non-randomised study, and there were no 
untreated or uninfected controls for comparison. The study sample was relatively small, with 
a high rate of loss to follow-up, resulting in a lack of power. There was minimal exposure to 
protease inhibitors, so we can only make inferences about first-line ART. Despite these 







In conclusion, we found that body fat changes differed in men and women on ART. Men, more 
frequently than women, developed lipoatrophy, while the risk of lipohypertrophy was no 
different in men and women. The percentage of trunk fat in women, but not men, increased 
significantly, with median BMI and VAT increasing substantially more in women than men. 
Further investigation is required to understand the mechanisms underlying the sex 
differences and its effects on cardiovascular risk. 
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Supplementary Table 4. Comparison of ART in all participants with ≥ 20% fat loss in limbs 








Supplementary Figure 1. Trends for DXA measures in men and women 
A: Arm fat (kg) 
Men p=0.211; Women p<0.001  
 
B: Arm fat (% of body fat) 
Men p=0.737; Women p=0.673 
 
C: Leg fat (kg) 
Men p=0.505; Women p<0.001 
 
D: Leg fat (% of body fat) 
Men p=0.340; Women p<0.001  
 
E: Body fat – excluding the head (kg) 
Men p=0.085; Women p<0.001 
 
F: Abdominal Total Adipose Tissue (kg) 










































































Supplementary Table 1. Comparison of anthropometric measures in men and women at baseline, 3, 6, 12, 18 and 24 months 
















Women n=132 n=103 n=102 n=88 n=77 n=66  
Height (m) 1.58 [1.55-1.62] 1.58 [1.54-1.62] 
 
1.58 [1.55-1.62] 1.58 [1.55-1.62] 1.57 [1.54-1.62] 1.58 [1.55-1.63] 0.340 
Weight (kg) 62.0 [54.7-71.3] 65.8 [57.5-73.6] 68.1 [58.2-77.0] 69.2 [59.3-82.8] 69.8 [59.8-81.8] 71.1 [57.6-84.4] <0.001 
BMI 24.8 [21.1-28.7] 26.3 [22.4-30.0] 27.1 [22.8-30.9] 27.8 [23.9-33.4] 28.3 [22.4-31.8] 27.7 [22.7-33.9] <0.001 
Men  n=55 n=43 n=45 n=35 n=31 n=26  
Height (m) 1.7 [1.7-1.8] 1.7 [1.7-1.7] 1.7 [1.7-1.8] 1.7 [1.7-1.8] 1.7 [1.7-1.7] 1.7 [1.7-1.7] 0.475 
Weight (kg) 61.0 [55.0-67.0] 62.1 [55.8-68.2] 63 [56.2-69.0] 65.0 [60.6-72.0] 65.0 [60.0-74.0] 65.2 [59.0-70.5] 0.009 






Supplementary Table 2. Comparison of DXA measures in women at baseline, 3, 6, 12, 18 and 24 months 
*Jonckheere-Terpstra test for ordered variables with an increasing trend 























Fat (kg) 2.19 [1.44-3.04] 2.36 [1.60-3.14] 2.71 [1.71-3.42] 3.0 [2.19-3.90] 2.91 [1.93-3.85] 3.0 [1.58-4.06] <0.001 
Fat (%) 10.7 [9.6-11.9] 10.6 [9.5-11.6] 10.8 [9.5-11.9] 10.6 [9.4-11.5] 10.5 [9.3-11.6] 10.8 [9.2-12.0] 0.673 
Legs 
Fat (kg) 9.08 [7.10-10.93] 9.60 [7.45-11.85] 10.66 [8.32-12.82] 11.12 [8.70-15.19] 10.602 [8.31-14.41] 10.47 [7.51-14.27] <0.001 
Fat (%) 45.2 [39.7-50.1] 45.1 [39.7-49.9] 44.5 [40.2-48.6] 43.9 [38.6-47.6] 42.3 [38.2-47.8] 42.1 [37.5-46.9]       <0.001** 
Limbs 
Fat (kg) 11.20 [8.67-14.16] 11.98 [9.10-14.7] 13.47 [10.26-15.82] 14.40 [10.70-18.79] 13.39 [10.57-18.55] 13.49 [9.29-18.02] <0.001 
Fat (%) 55.8 [50.8-60.4] 55.5 [51.2-59.6] 55.3 [51.4-59.2] 54.3 [50.1-57.9] 53.1 [50.1-57.3] 52.3 [49.5-56.3]     <0.001** 
Trunk 
Fat (kg) 7.61 [5.51-11.9] 8.57 [5.97-12.37] 9.95 [6.67-13.86] 12.32 [8.23-15.84] 11.99 [6.96-16.49] 11.69 [6.79-17.33] <0.001 
Fat (%) 42.0 [37.2-47.4] 42.4 [37.7-47.2] 43.1 [38.0-47.1] 44.1 [39.3-48.6] 45.2 [39.6-48.9] 46.2 [40.1-49.3] <0.001 
Whole body (excluding the head) 
Fat (kg) 19.70 [14.41-26.56] 20.84 [15.01-26.79] 23.42 [16.26-29.66] 26.92 [18.57-34.19] 25.64 [18.67-32.65] 24.52 [15.54-35.08] <0.001 
Abdominal Adipose Tissue 
Subcutaneous (SAT) (kg) 1.20 [0.88-1.88] 1.34 [0.90-1.99] 1.50 [1.05-2.15] 1.81 [1.21-2.31] 1.78 [1.09-2.32] 1.87 [1.03-2.43] <0.001 
Visceral (VAT) (kg) 0.32 [0.21-0.48] 0.34 [0.22-0.48] 0.38 [0.24-0.52] 0.46 [0.28-0.52] 0.50 [0.29-0.72] 0.51 [0.26-0.70] <0.001 






Supplementary Table 3. Comparison of DXA measures in men at baseline, 3, 6, 12, 18 and 24 months  























Fat (kg) 0.80 [0.61-1.31] 0.82 [0.64-1.15] 0.90 [0.61-1.11] 1.02 [0.75-1.32] 1.00 [0.63-1.26] 0.86 [0.69-1.12] 0.106 
Fat (%) 9.0 [8.4-10.0] 8.7 [7.9-9.9] 8.8 [8.0-9.4] 9.1 [8.4-9.8] 9.3 [8.4-9.8] 9.3 [8.6-9.8] 0.368 
Legs 
Fat (kg) 3.48 [2.37-5.09] 3.77 [2.5-4.95] 3.90 [2.88-5.24] 4.25 [3.32-5.08] 4.04 [2.67-4.84] 3.47 [2.59-4.74] 0.252 
Fat (%) 37.0 [34.3-41.2] 37.7 [35.1-41.5] 38.3 [35.7-41.5] 38.1 [34.1-41.3] 37.0 [33.6-40.7] 37.3 [33.7-38.8] 0.830 
Limbs 
Fat (kg) 4.32 [3.03-6.41] 4.60 [3.09-6.06] 4.65 [3.54-6.26] 5.41 [4.02-6.07] 5.18 [3.15-5.98] 4.37 [3.27-5.92] 0.211 
Fat (%) 47.1 [43.0-50.4] 47.6 [43.6-50.2] 47.5 [44.6-51.1] 48.6 [43.4-49.9] 46.0 [40.8-50.0] 45.1 [43.4-48.7] 0.876 
Trunk 
Fat (kg) 3.65 [2.87-5.49] 3.81 [3.01-5.15] 3.89 [2.99-5.66] 4.26 [3.23-6.25] 4.61 [3.37-6.32] 4.16 [3.07-5.94] 0.027 
Fat (%) 48.2 [44.7-51.4] 47.8 [43.8-50.4] 47.8 [44.2-49.7] 46.8 [44.5-51.2] 49.4 [45.4-52.9] 50.1 [45.1-52.1] 0.085 
Whole body (excluding the head)  
Fat (kg) 7.81 [6.21-12.01] 8.42 [6.46-11.37] 8.80 [6.66-11.72] 9.74 [7.24-12.72] 9.87 [6.92-11.99] 8.38 [6.34-11.69] 0.091 
Adipose Tissue 
Subcutaneous (SAT) (kg) 0.33 [0.26-0.46] 0.36 [0.28-0.56] 0.37 [0.25-0.59] 0.40 [0.30-0.71] 0.47 [0.30-0.61] 0.38 [0.27-0.54] 0.049 
Visceral (VAT) (kg) 0.25 [0.21-0.33] 0.25 [0.20-0.33] 0.27 [0.21-0.35] 0.27 [0.23-0.42] 0.31 [0.24-0.41] 0.29 [0.22-0.41] 0.032 






Supplementary Table 4. Comparison of ART in all participants with ≥ 20% fat loss in limbs 










 n* [%] P-value n* [%] P-value n* [%] P-value n* [%] P-value n* [%] P-value 
D4T 2 [100] <0.001 2 [100] <0.001 4 [66.7] <0.001 4 [57.1] <0.001 4 [66.7] <0.001 
AZT 0 0.001 0 0.002 1 [16.7] 0.210 0 0.359 0 0.791 
D4T + AZT 2 [100] <0.001 2 [100] <0.001 5 [83.3] <0.001 4 [57.1] <0.001 4 [66.7] <0.001 
TDF 0 <0.001 0 <0.001 1 [16.7] <0.001 3 [42.8] <0.001 2 [33.3] <0.001 
EFV 0 <0.001 1 [50.0] <0.001 1 [16.7] <0.001 4 [57.1] <0.001 3 [50.0] <0.001 
NVP 2 [100] <0.001 1 [50.0] <0.001 5 [83.3] <0.001 3 [42.8] <0.001 3 [50.0] <0.001 







Supplementary Table 5. Comparison of ART in participants with ≥ 20% fat gain in trunk 











n* [%] P-value** n* [%] P-value** n* [%] P-value** n* [%] P-value** n* [%] P-value** 
D4T 16 [72.7] <0.001 24 [66.7] <0.001 30 [61.2] 0.119 27 [58.7] 1 15 [55.5] 0.215 
AZT 1 [4.5] 
0.405 
 
1 [2.7] 0.004 5 [10.2] <0.001 5 [10.9] <0.001 3 [11.1] <0.001 
D4T + AZT 17 [77.3] <0.001 25 [69.4] <0.001 35 [71.4] 0.001 32 [69.6] 0.108 18 [66.7] 0.009 
TDF 5 [22.7] 0.006 11 [39.6] 0.504 14 [28.6] 0.040 14 [30.4] 0.126 9 [33.3] 1 
EFV 13 [59.1] <0.001 18 [50.0] 0.085 17 [34.7] 0.126 17 [36.9] 0.049 10 [37.0] 0.860 
NVP 9 [40.9] <0.001 18 [50.0] <0.001 32 [65.3] 0.009 29 [63.1] 0.079 17 [63.0] 0.008 
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Lipohypertrophy does not appear to be an adverse ART reaction while lipoatrophy is clearly 
associated with the use of stavudine and zidovudine. In low- and middle-income countries 
stavudine has only recently been phased out and zidovudine is still widely being used. Several 
case definitions have been developed to diagnose lipodystrophy, but none of them are 
generalizable to sub-Saharan Africa where black women have less visceral adipose tissue and 
more subcutaneous adipose tissue than white women. We aimed to develop a simple, 
objective measure to define lipoatrophy and lipohypertrophy by comparing patient report to 
anthropometric and dual-energy X-ray absorptiometry (DXA) -derived variables. 
Methods 
DXA and anthropometric measures were obtained in a cross sectional sample of black HIV-
infected South African men (n=116) and women (n=434) on ART. Self-reported information 
on fat gain or fat loss was collected using a standard questionnaire. Receiver operating 
characteristic (ROC) curves were used to describe the performance of anthropometric and 
DXA-derived variables using patient reported lipoatrophy and lipohypertrophy as the 
reference standard. 
Results 
Lipoatrophy and lipohypertrophy were more common in women (25% and 33%, respectively) 
than in men (10% and 13%, respectively). There were insufficient numbers of men with DXA 
scans for meaningful analysis. The best predictors of lipoatrophy in women were the 
anthropometric variables triceps (AUC = 0.725) and thigh skinfold (AUC = 0.720) thickness; 
and the DXA-derived variables percentage lower limb fat (AUC = 0.705) and percentage lower 
limb fat/height (AUC = 0.713). The best predictors of lipohypertrophy in women were the 
anthropometric variable waist/hip ratio (AUC = 0.645) and the DXA-derived variable 







We were able to develop simple, anthropometric measures for defining lipoatrophy and 
lipohypertrophy, using a sample of black HIV-infected South African women with DXA scans. 
This is of particular relevance in resource limited settings, where health professionals need 




Antiretroviral therapy (ART) has significantly reduced the morbidity and mortality of people 
infected with HIV [1], however, long-term use of ART has been associated with a number of 
metabolic complications such as dysglycaemia, insulin resistance, dyslipidaemia and 
lipodystrophy [2]. Lipodystrophy is characterized by either subcutaneous fat loss, which is 
most noticeable in the face, limbs, and buttocks (lipoatrophy), or fat accumulation 
(lipohypertrophy) seen in the abdomen, breast or posterior neck, or a combination of both 
[3,4]. 
Both subjective and objective methods have been used to diagnose lipodystrophy, resulting 
in a number of case definitions. The most widely used subjective methods of diagnosis are 
patient perception and report [5,6], physician examination and report [7], and physician 
confirmation of patient report [8-11]. Objective measures used are imaging by dual-energy X-
ray absorptiometry (DXA) [6,12,13] and computed tomography (CT) scans [12,14]. These 
imaging measures are expensive and not widely available in resource limited settings. 
Anthropometric and DXA-derived variables have also been developed, in an attempt to 
provide standard measures of defining lipodystrophy [15-17]. Furthermore, criteria 
established to define lipodystrophy did not include data from any African country. These 
diagnostic criteria may not be generalizable to sub-Saharan Africans, as there are important 
ethnic differences in fat distribution, especially in black women who have less visceral adipose 






Lipohypertrophy does not appear to be an adverse ART reaction as participants on different 
ART drug regimens gained similar amounts of trunk fat over time [21]. Lipoatrophy, in contrast 
is clearly an adverse ART reaction. The use of stavudine and zidovudine is associated with 
subcutaneous fat loss and is partially reversed after changing to abacavir or tenofovir [21,22]. 
Lipoatrophy remains common in low- and middle-income countries where stavudine has only 
recently been phased out and zidovudine is still widely used [23].  However, even if 
lipohypertrophy is not associated with ART, lipodystrophy, and lipoatrophy in particular, is 
independently associated with an increased risk of vascular disease [24,25]. Therefore 
recognising lipodystrophy is important to identify patients at risk for vascular disease so that 
screening can be targeted for other vascular risk factors, while recognising lipoatrophy is 
important so that stavudine or zidovudine can be substituted. 
The aim of our study was to develop a simple, objective measure to define lipoatrophy and 
lipohypertrophy by comparing patient report to anthropometric and DXA-derived variables in 
a sample of black South Africans on ART. 
6.3 Methods 
Participants 
A convenience sample of HIV-infected black men and women presenting to ART clinics in Cape 
Town were selected. The recruitment procedure is described elsewhere [26]. The study 
sample comprised 116 men and 434 women on ART. At the time of the study two ART 
regimens were available to South Africans accessing primary health care facilities. The first-
line ART regimen consisted of stavudine, lamivudine and efavirenz or nevirapine, and a 








Questionnaires were used to collect socio-demographic information from participants. Their 
clinical records at the health facilities were reviewed to obtain data on ART regimen, time on 
ART, and CD4 count. Self-reported information on fat gain or fat loss was collected using a 
standard questionnaire [8]. Lipoatrophy was defined as moderate or severe fat loss in two or 
more regions and lipohypertrophy defined as moderate or severe fat gain in two or more 
areas [28].  
Anthropometric measurements: [weight, height, circumferences (waist, hip, mid-upper arm, 
and mid-thigh), skinfold thickness (biceps, triceps, subscapular, abdomen, supra-iliac, thigh 
and calf) and sagittal abdominal diameter (SAD)] were taken and have previously been 
described [29].  DXA (Hologic Discovery-W, software version 12.7; scan region 195 x 65 cm2 
and weight limit 160 kg) was used to measure fat mass and fat free soft tissue mass in a 
subsample of participants (women: n = 172; men: n = 53). DXA cut-off lines positioned at 
anatomical markers were used to obtain fat mass for the whole body as well as for the various 
regions of interest. A more detailed description has been previously described [26]. 
Ethical Approval 
The study proposal was submitted and approved by the Research Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town. Written informed consent was 
obtained from all participants prior to participation in the study. 
Data Analyses 
Data analysis was carried out using the STATA/SE statistical software package version 12.0 
(StataCorp., College Station, TX, USA). Data were collected between February 2007 and June 
2009. Participants were categorised into those with and those without lipoatrophy. 
Continuous variables were described as medians and inter-quartile ranges (IQR), and were 







Receiver operating characteristic (ROC) curves were used to describe the performance of a 
number of anthropometric and DXA-derived variables using patient reported lipoatrophy and 
lipohypertrophy as the reference standard.  The area under the curve (AUC) was used to 
assess the diagnostic performance of each variable. In addition, sensitivity, specificity, 
likelihood ratios and predictive values were calculated for variables with the highest AUC at 
the optimum cut-points. Cut-point selection was based on positive likelihood ratios. 
6.4 Results 
Participant characteristics are presented in Table 1. The study sample consisted of 550 
participants on ART. Based on patient report, 121 (22%) had lipoatrophy and 157 (29%) had 
lipohypertrophy. Both lipoatrophy and lipohypertrophy were significantly more common in 
women than in men (p≤0.001). Participants with lipoatrophy had spent a significantly longer 
period of time on ART (25 months vs. 17 months) and a longer time on stavudine (15.5 months 
vs. 13 months).  
Anthropometric variables are shown separately for women and men (Tables 2 and 3 
respectively). In women, all median skinfold measurements, with the exception of sub-
scapular skinfold thickness, were significantly lower in participants with lipoatrophy 
compared with those without lipoatrophy. Measurements for waist circumference, waist/hip 
ratio and supra-iliac skinfold thickness were significantly higher in women with 
lipohypertrophy compared with those without lipohypertrophy. There were no statistically 
significant differences in anthropometric variables in men with and without lipoatrophy 
(Table 3). Men with lipohypertrophy had a significantly (P=0.008) greater thigh circumference 
than those without (13.5 mm vs. 8.1 mm).   
DXA-derived measures are shown for women only (Table 4), as there were insufficient 
numbers of men with DXA scans for meaningful analysis. Women with lipoatrophy as well as 
those with lipohypertrophy, had a significantly higher percentage trunk fat/lower limb fat and 






Women with lipoatrophy had significantly less percentage limb fat while women with 












With Without With Without 
Median [IQR] Median [IQR] Median [IQR] Median [IQR] 
n=121 n=429 n=157 n=393 
Age 34 [30-42] 35 [30-41] 0.256 34 [29-41] 35 [30-41] 0.198 
Current CD4 count 397 [249-539] 315 [218-481] 0.023 389 [248-548] 314 [220-481] 0.015 
Time on ART (months)  25 [14-32] 17 [10-27] 0.001 20 [12-31] 17 [11-28] 0.080 
Time on Stavudine (months) 15.5 [10-26] 13 [8-19] 0.004 13 [8-21] 13 [9-20] 0.961 
       
 n [%] n [%]  n [%] n [%]  
Sex       
Men  12 [10.34] 104 [89.66] 0.001 15 [12.93] 101 [87.07] <0.001 
Women 109 [25.12] 325 [74.88]  142 [32.72] 292 [67.28]  
Highest standard passed       
No schooling 6 [18.8] 26 [81.3] 0.289 9 [28.13] 23 [71.88] 0.272 
Primary school 14 [15.4] 77 [84.6]  20 [21.98] 71 [78.02]  
Secondary school 96 [23.4] 315 [76.6]  121 [29.44] 290 [70.56]  
Tertiary  5 [31.3] 11 [68.8]  7 [43.75] 9 [56.25]  
ART Regimen       
First-line 99 [22.30] 345 [77.70] 0.730 130 [29.28] 314 [70.72] 0.608 
Second-line 22 [20.75] 84 [79.25]  27 [25.47] 79 [74.53]  
*based on patient report, those with moderate or severe fat loss in 2 or more regions 
**Wilcoxon Rank-sum (Mann-Whitney) tests for continuous variables and chi-square tests for binary variables 












With Without With Without 
Median[IQR] Median [IQR] Median [IQR] Median [IQR] 
n=106 n=312 n=142 n=292 
Height (m) 1.6 [1.5-1.6] 1.6 [1.5-1.6] 0.603 1.6 [1.6-1.6] 1.6 [1.5-1.6] 0.112 
Weight (kg) 65.4 [56.0-74.5] 68.1 [58.9-80.9] 0.019 69.5 [60.7-80.4] 67.1 [57.6-79.3] 0.127 
BMI 26.2 [23.8-29.3] 27.1 [24.1-31.6] 0.036 27.4[24.6-31.3] 26.65[23.9-31.2] 0.187 
Sagittal Abdominal Diameter (cm) 20.5 [19.0-23.0] 20.0 [18.5-23.0] 0.552 21[19-24] 20[18-23] 0.004 
Circumferences       
Waist (cm) 86.3 [79.5-96.3] 87.0 [78.5-97.0] 0.704 90.7[80.3-98.5] 86[78.4-95] 0.003 
Hip (cm) 98.0 [92.0-104.0] 102.0 [95.0-
112.0] 
<0.001 100[95-110] 101[94-110] 0.824 
Waist/hip ratio 0.90 [0.83-0.94] 0.85 [0.80-0.90] <0.001 0.89[0.83-0.93] 0.84[0.79-0.90] <0.001 
Mid-upper arm (cm) 27.0 [25.0-29.0] 29.0 [26.5-32.0] <0.001 28[26-32] 28[26-32] 0.789 
Mid-thigh (cm) 54.5 [51.0-59.0] 57.0 [53.0-63.0] <0.001 56[52-61] 57[52-63] 0.589 
Skinfolds       
Bicep (mm) 6.0 [4.4-8.4] 8.1 [5.7-11.7] <0.001 7.1[5.2-10.7] 8[5.4-11.45] 0.189 
Triceps (mm) 13.3 [9.5-17.4] 18.4 [13.6-26.0] <0.001 16.2[12-22] 18.3[13-25.15] 0.059 
Abdomen (mm) 20.4 [11.9-30.0] 24.4 [16.8-35.3] 0.001 24.1[15.9-35.8] 23.6[15.0-31.2] 0.210 
Thigh (mm) 23.8 [15.4-32.8] 34.7 [24.2-44.7] <0.001 29.8[20.5-42.5] 32.0[22.5-43.5] 0.359 
Sub-Scapular (mm) 16.9 [12.5-23.0] 19.2 [12.2-28.8] 0.058 20[14.8-29.4] 18.5[11.7-27.1] 0.050 
Supra-iliac (mm) 13.2 [7.7-18.7] 15.1 [8.8-22.8] 0.033 16.6[9.9-24.0] 13.9[8.2-21.7] 0.022 
Calf (mm)  10.8 [8.0-17.5] 17.5 [12.2-24.2] <0.001 15.6[9.2-21.3] 17.3[11.4-23.6] 0.061 
*based on patient report, those with moderate or severe fat loss in 2 or more regions 
**Wilcoxon Rank-sum (Mann-Whitney) tests for continuous variables and chi-square tests for binary variables 













With Without With Without 
Median [IQR] Median [IQR] Median [IQR] Median [IQR] 
n=12 n=104 n=15 n=101 
Height (m) 1.7 [1.6-1.7] 1.7 [1.6-1.7] 0.942 1.7 [1.6-1.8] 1.7 [1.7-1.7] 0.954 
Weight (kg) 65.5 [59.7-68.6] 63.5 [57.0-74.4] 0.895 67.4 [57.8-78.3] 62.7 [57.3-73.4] 0.408 
BMI 23.3 [20.2-23.9] 22.4 [20.6-25.2] 0.772 23.6 [21.1-25.5] 22.3 [20.5-24.8] 0.324 
Sagittal Abdominal Diameter (cm) 17.0 [16.0-19.5] 18.0 [17.0-20.0] 0.384 17.0 [16.0-22.0] 18.0 [17.0-20.0] 0.967 
Circumferences       
Waist (cm) 81.75 [77-84.9] 80.4 [75.0-90.2] 0.953 83.8 [75.0-97.0] 79.8 [75.8-89.5] 0.338 
Hip (cm) 90 [87-93.5] 90.0 [85.0-97.0] 0.768 91.0 [85.0-97.0] 90.0 [85.0-96.0] 0.556 
Waist/hip ratio 0.89 [0.85-0.95] 0.91 [0.87-0.94] 0.740 0.93 [0.86-0.97] 0.90 [0.86-0.94] 0.325 
0.325 Mid-upper arm (cm) 27.0 [24-28.5] 26.0 [24.0-29.0] 0.877 27.0 [25.0-29.0] 26.0 [24.0-29.0] 0.817 
Mid-thigh (cm) 50.5 [43.5-52.5] 49.0 [46.0-54.0] 0.401 49.0 [46.0-56.0] 49.0 [46.0-54.0] 0.567 
Skinfolds       
Bicep (mm) 3.9 [3.4-4.2] 3.5 [3.0-4.5] 0.329 4.1 [3.2-4.8] 3.5 [3.0-4.3] 0.180 
Triceps (mm) 6.8 [5.6-8.2] 6.4 [5.1-9.3] 0.921 8.4 [5.0-11.4] 6.4 [5.1-8.7] 0.444 
Abdomen (mm) 13.5 [10.5-16.9] 12.3 [8.5-30.1] 1.00 15.8 [9.3-28.2] 12.3 [8.5 -18.1] 0.309 
Thigh (mm) 8.4 [7.2-14.8] 8.5 [6.0-12.4] 0.490 13.5 [8.4-21.1] 8.1 [6.0-11.3] 0.008 
Sub-Scapular (mm) 9.4 [6.5-13.2] 8.3 [6.3-13.4] 0.605 10.5 [5.7-18.0] 8.2 [6.5-11.1] 0.770 
Supra-iliac (mm) 6.3 [4.4-6.8] 6.2 [4.9-9.4] 0.196 6.4 [4.7-12.1] 6.2 [4.9-8.5] 0.934 
Calf (mm)  5.5 [4.8-9.0] 5.8 [4.4-8.2] 0.739 6.8 [5.4-10.5] 5.5 [4.4-7.7] 
 
0.094 
*based on patient report, those with moderate or severe fat loss in 2 or more regions 
**Wilcoxon Rank-sum (Mann-Whitney) tests for continuous variables and chi-square tests for binary variables 













With Without With Without 
Median [IQR] Median [IQR] Median [IQR] Median [IQR] 
n=29 n=143 n=46 n=126 
DXA-derived measures       
Arm fat (%) 37.4 [30.8-44.1] 38.3 [31.8-47.1] 0.380 39.8 [31.5-48.3] 38.1 [31.7-45.1] 0.319 
Lower limb fat (%) 37.6 [31.5-40.6] 43.4 [36.6-49.7] 0.001 39.2 [33.3-49.7] 41.8 [36.3-48.8] 0.761 
Trunk fat (%) 34.7 [29.9-38.0] 35.1 [27.9-43.1] 0.719 37.9 [30.7-45.3] 34.4 [26.6-40.4] 0.019 
Lower limb fat/ht (%) 23.6 [19.7-25.4] 27.4 [23.4-31.5] 0.001 25.4 [21.9-31.1] 26.5 [23.2-29.7] 0.631 
Total limb fat/ht (%) 22.7 [20.8-27.0] 25.4 [22.0-29.9] 0.015 25.4 [20.8-31.1] 25.2 [21.8-29.1] 0.825 
Lower limb fat/BMI (%) 1.3 [1.2-1.7] 1.6 [1.3-1.8] 0.049 1.4 [1.2-1.6] 1.6 [1.3-1.8] 0.019 
Total limb fat/BMI (%) 1.3 [1.3-1.6] 1.5 [1.3-1.6] 0.193 1.3 [1.2-1.5] 1.5 [1.3-1.7] 0.006 
Trunk fat/lower limb fat (%) 0.94 [0.76-1.15] 0.83 [0.66-0.96] 0.017 0.93 [0.80-1.10] 0.81 [0.66-0.94] 0.003 
Trunk fat/ total limb fat (%) 1.0 [0.8-1.0] 0.9 [0.7-1.0] 0.045 0.93 [0.85-1.03] 0.85 [0.72-0.97] 0.003 
*based on patient report, those with moderate or severe fat loss in 2 or more regions 
**Wilcoxon Rank-sum (Mann-Whitney) tests for continuous variables and chi-square tests for binary variables 








ROC curves for lipoatrophy and lipohypertrophy were generated and reported in women for 
anthropometric and DXA-derived variables with the highest AUCs (Figure 1). For lipoatrophy, 
the two anthropometric variables with the highest AUCs were triceps skinfold thickness 
(AUC=0.725) and thigh skinfold thickness (AUC=0.720) and for lipohypertrophy they were 
waist/hip ratio (AUC=0.645) and waist circumference (AUC=0.589).  For lipoatrophy, the two 
DXA-derived variables with the highest AUC were the percentage of lower limb fat 
standardised to height (AUC=0.713) and percentage lower limb fat (AUC=0.705); and for 
lipohypertrophy they were percentage trunk fat/percentage total limb fat (AUC=0.647) and 
percentage trunk fat/percentage lower limb fat (AUC=0.646). An illustration of 
anthropometric and DXA-derived variables in women is shown in Figure 2.  
Optimum cut-points for lipoatrophy and lipohypertrophy variables, based on likelihood ratios, 
were selected. Table 5 shows the sensitivity, specificity, likelihood ratios and predictive values 
for the two anthropometric and DXA-derived variables with the highest AUCs for lipoatrophy 






Figure 1. ROC curves for the 2 anthropometric and DXA-derived variables with the highest 
AUC for lipoatrophy (A) and lipohypertrophy (B) in women on ART 
A: Lipoatrophy 
Triceps Skinfold [AUC=0.725] Thigh Skinfold [AUC=0.720] 
 
 
% Lower limb fat/height [AUC=0.713] Lower limb fat (%) [AUC=0.705] 
  
B: Lipohypertrophy 
Waist/Hip Ratio [AUC=0.645] Waist Circumference [AUC=0.589] 
  
















































































































































































































Figure 2. Lipoatrophy variables for women on ART with ROC AUC’s of ≥0.6 and their 95% 









Table 5: Variables for prediction and classification used to identify lipoatrophy and lipohypertrophy cut-points in women on ART 


















Lipoatrophy variable cut-point         
Triceps skinfold ≤14.5 mm 418 0.62 0.71 2.13 0.53 0.42 0.85 68.66* 
Thigh skinfold ≤28.0 mm 417 0.67 0.65 1.93 0.51 0.39 0.85 65.70* 
% Lower limb fat/height ≤ 24.7 418 0.19 0.85 1.28 0.95 0.30 0.76 68.42* 
Lower limb fat (%) ≤ 39.1 418 0.19 0.84 1.20 0.96 0.29 0.75 67.70* 
         
Lipohypertrophy variable cut-point         
Waist/Hip Ratio ≥ 0.899 434 0.44 0.75 1.75 0.75 0.46 0.73 64.75** 
Waist Circumference ≥ 88.5 cm 434 0.57 0.59 1.40 0.73 0.41 0.73 58.53** 
Trunk fat/total limb fat (%) ≥0.8895 172 0.50 0.70 1.66 0.72 0.38 0.79 64.5** 
Trunk fat/leg fat (%) ≥ 0.8816 172 0.72 0.61 1.84 0.46 0.40 0.86 64.0** 
*percentage of those classified with and without lipoatrophy using the new cut-point compared to those defined by subject-report 






We showed that simple anthropometric measures were at least as good as DXA-derived 
measures to diagnose lipoatrophy and lipohypertrophy in African women on ART. The best 
predictors of lipoatrophy in women were the anthropometric variables triceps and thigh 
skinfold thicknesses; and the DXA-derived variables percentage lower limb fat and percentage 
lower limb fat/height. The best predictors of lipohypertrophy in women were the 
anthropometric variable waist/hip ratio and the DXA-derived variable percentage trunk 
fat/percentage limb fat. Women with lipoatrophy had considerably smaller limb 
circumferences, limb skinfold thicknesses and lower percentages of limb fat than women 
without lipoatrophy, despite similar BMIs. Lipoatrophy and lipohypertrophy were both more 
common in women than in the small sample of men. 
Previous studies, conducted in high-income countries, developed objective measures for 
lipodystrophy, thus combining lipoatrophic and lipohypertrophic individuals [15-17]. They 
proposed the use of fat mass ratio (FMR), defined as the ratio between the percentage of 
trunk fat mass and the percentage of lower limb fat mass. We however sought to investigate 
lipoatrophy and lipohypertrophy as separate entities. Identification of lipoatrophy is 
important as it is an adverse antiretroviral drug reaction, which improves on switching 
antiretroviral drugs [21]. Although lipohypertrophy is thought to be a consequence of treating 
the HIV infection rather than an adverse antiretroviral drug reaction [21], like lipoatrophy, it 
is associated with an increased risk of vascular disease [30] therefore it is worth identifying so 
that appropriate screening and prevention interventions can be implemented.  
Despite the subjective nature of assessing lipoatrophy and lipohypertrophy by using patient 
self-report, previous studies have shown a strong correlation between patient and physician 
reported lipodystrophy scores [31-33]. In South Africa, as well as in many other African 
countries, nurses, rather than physicians, prescribe antiretroviral therapy and follow-up 
patients. For these reasons we used patient self-report [5, 6] as the reference measure to 




Our study, like several others [11, 21], showed a significant association between lipoatrophy 
and time on ART, and time on stavudine in particular. As South Africa has only recently phased 
out stavudine, and zidovudine is still being used, it is not unexpected that a quarter of the 
women and a tenth of the men, had lipoatrophy. The prevalence of lipoatrophy found in this 
study is not easy to compare with other studies, as studies from high-income countries 
focussed on men [12, 24], while most studies from Africa looked at the prevalence of 
lipodystrophy [34-36] rather than studying the two entities of lipoatrophy and lipodystrophy 
separately. Our finding that triceps skinfold thickness was a predictor of lipoatrophy is 
supported by other studies. George et al. [37], using a small sample of HIV-infected South 
Africans, found that after two years of exposure to ART, patients had significantly decreased 
triceps skinfold thickness. Similarly, a Ugandan study using a sample of HIV-infected men and 
women [36], found that decreased triceps skinfold thicknesses was associated with the use 
of zidovudine.   
There were some limitations to our study. The cross sectional design, while allowing us to 
make associations, does not allow us to infer causality. With changes in fat distribution, 
repeated objective measures would have given us a better reference standard than patient 
report, even though patient report is commonly used [5, 6]. We did not have enough men 
with lipoatrophy or lipohypertrophy, to explore predictive anthropometric and DXA-derived 
variables.  Finally, the likelihood ratios for the most predictive anthropometric and DXA-
derived variables were only weakly diagnostic of self-reported lipoatrophy and 
lipohypertrophy. Future research of longitudinal studies in African cohorts, using changes in 
DXA-derived variables as the reference standard, is needed to confirm the value of 
anthropometric measures for the diagnosis of lipoatrophy and lipohypertrophy. 
6.6 Conclusion 
Using a large sample of black HIV-infected South African women who had DXA scans 
performed, we were able to develop anthropometric measures for defining lipoatrophy and 
lipohypertrophy. The development of anthropometric measures which admittedly needs 




relevance in resource limited settings, where health professionals need simple and 
inexpensive methods of diagnosing patients with lipoatrophy and lipohypertrophy.  
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Anthropometric definitions for antiretroviral associated 
lipodystrophy derived from a longitudinal South African cohort with 
dual-energy X-ray absorptiometry data 
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The development of lipodystrophy is associated with the long-term use of antiretroviral 
therapy (ART).  The diagnosis of lipodystrophy is difficult in resource-limited settings because 
of limited facilities for imaging, e.g. dual-energy X-ray absorptiometry (DXA), to show changes 
in body fat distribution.  We assessed the agreement between patient reported lipodystrophy 
(using a standard instrument) and anthropometry with body fat changes measured using DXA 
to develop objective measures to define lipoatrophy and lipohypertrophy in a sample of black 
South Africans on ART. 
Methods 
ART-naïve HIV-infected adults were enrolled in a 24 month longitudinal study. Self-reported 
information on regional fat loss and fat gain, anthropometry, and DXA measures were 
collected at baseline, and at 3 months, 6 months, 12 months, 18 months, and 24 months after 
starting ART. Receiver operating characteristic (ROC) curves were used to describe the 
performance of anthropometric variables using change in limb and trunk fat measured by 
DXA as the reference standard. 
Results 
The proportion of men and women who developed lipoatrophy increased over the 24 month 
period, but it occurred more frequently in men (21.4% vs. 9.6%). Thigh skinfold and mid-arm 
circumference cut-points performed best at predicting lipoatrophy in women (correctly 
classifying 80% and 78%, respectively); and mid-arm circumference in men (correctly 
classifying 70%). Anthropometric measures performed poorly at defining DXA-defined 
lipohypertrophy. We showed very poor agreement between patient reported lipoatrophy and 





This is the first study from sub-Saharan Africa to describe longitudinal changes in body fat 
composition using DXA-derived measures.  Anthropometric measures performed well for 
defining lipoatrophy, but not lipohypertrophy, in both men and women using DXA-derived 
measures as the reference standard.  
7.2 Introduction 
Long-term use of antiretroviral therapy (ART) is associated with a number of metabolic 
complications, including fat redistribution or lipodystrophy. Lipodystrophy is an all-
encompassing term used to refer to lipoatrophy (loss of subcutaneous fat, particularly in the 
face and limbs), lipohypertrophy (increase in fat, particularly around the abdomen and 
breast), or a combination of both [1]. As both lipoatrophy and lipohypertrophy are associated 
with an increased risk of cardiovascular disease [2-4], it is important that simple, objective 
measures to diagnose lipodystrophy be developed for HIV care and treatment.  
Lipodystrophy has been diagnosed using both subjective (self-report and examination by a 
clinician) [5-7] and objective methods (computed tomography, magnetic resonance imaging, 
and dual-energy X-ray absorptiometry (DXA)) [8-11]. Diagnosing lipodystrophy using costly 
objective methods is problematic, especially in resource limited settings [12] where self-
report using standardised questionnaires, and clinical examination are the most commonly 
used assessment methods. While some studies found a high level of agreement between self-
report and clinical examination [13,14], others reported poor agreement [15,16]. A cross-
sectional study comparing patient and physician report to DXA-measured limb fat showed 
reasonable levels of agreement between lipoatrophy scores as measured by questionnaire 
and DXA-measured limb fat [17]. Studies on the diagnosis of lipodystrophy have mostly been 
done in men from high-income countries. There is minimal data on diagnosing lipodystrophy 
in sub-Saharan Africa, which bears the brunt of the HIV epidemic and where more women are 
infected than men. There is a high prevalence of obesity in black South African women and 




anthropometric cut-points to diagnose lipodystrophy in a cross-sectional study, but the 
reference standard was patient report [11].  
Therefore, the aim of our study was, firstly, to develop objective measures to define 
lipoatrophy and lipohypertrophy by comparing change in limb fat and trunk fat as measured 
by DXA to anthropometric variables; and secondly, to assess agreement between patient 
reported lipoatrophy and lipohypertrophy with objective measures derived by DXA in a 
sample of black South Africans starting ART. 
7.3 Methods 
Participants  
A convenience sample of ART-naive HIV-infected men and women presenting at Crossroads 
Community Health Centre in Cape Town were enrolled in a 24 month longitudinal study. 
Patients were initiated on ART after enrolment into the study and completion of baseline 
evaluations. During the course of the study there was a change in the nucleoside reverse 
transcriptase inhibitors (NRTIs) used in first-line ART regimens in South Africa, from stavudine 
or zidovudine to tenofovir, together with lamivudine, and efavirenz or nevirapine. The 
second-line ART regimen consisted of zidovudine, lamivudine and lopinavir/ritonavir [19]. 
Testing procedures 
Socio-demographic information was collected from participants at the beginning of the study 
using an interviewer administered questionnaire. The Lipodystrophy Case Definition 
questionnaire [6] was used to collect self-reported information on fat gain or fat loss. Self-
reported lipoatrophy was defined as moderate or severe fat loss in two or more regions, and 
self-reported lipohypertrophy was defined as moderate or severe fat gain in two or more 
areas [20].  Anthropometry and DXA were performed at baseline, 3 months, 6 months, 12 
months, 18 months, and 24 months. All anthropometric measurements were performed by 
the same anthropometrist and included weight, height, circumferences (waist, hip, mid-upper 




triceps, subscapular, abdomen, supra-iliac, thigh and calf). DXA (Discovery-W®, software 
version 12.7.3.7; Hologic, Bedford, MA) was used to measure fat mass according to standard 
procedures by an independent observer. DXA cut-off lines positioned at anatomical markers 
were used to obtain fat mass for the whole body as well as for the various regions of interest 
(arms, legs and trunk). The trunk comprised the region between the neck and waist, excluding 
the arms. Limb composition was determined by summing the arms and legs. Clinical records 
obtained from health facilities were reviewed to obtain information on ART regimens, viral 
loads and CD4 counts. 
Ethical approval 
The study proposal was submitted and approved by the Research Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town. Written informed consent was 
obtained from all participants prior to participation in the study.  
Data analysis 
Data analysis was carried out using the STATA/SE statistical software package version 14.1 
(StataCorp., College Station, TX, USA). Continuous variables were described as medians and 
inter-quartile ranges (IQR), and were compared using Wilcoxon Rank Sum tests. Binary 
variables were described using frequency and percentages, and compared using chi-square 
tests. The Jonckheere-Terpstra test for ordered variables was used to measure trends over 
time.  
Two DXA-defined definitions of lipoatrophy were explored for the development of 
anthropometric measures: (1) ≥ 20% loss of limb fat from baseline [21] and, (2) ≥ 10% loss of 
limb fat (all limbs combined) from baseline by DXA scan [22]. Lipohypertrophy was defined as 
≥ 20% gain in trunk fat from baseline by DXA scan [23,24]. Receiver operating characteristic 
(ROC) curves were used to describe the performance of a number of anthropometric variables 
in men and women using DXA-defined lipoatrophy and lipohypertrophy as the reference 
standard at 12, 18, and 24 months on ART.  Anthropometric variable selection was based on 
associations with lipoatrophy or lipohypertrophy. The area under the ROC curve (AUC) was 




likelihood ratios and predictive values were calculated for variables with ROC AUCs of ≥ 0.65 
at the optimum cut-points. Cut-point selection was based on positive likelihood ratios.  
7.4 Results 
ART-naïve participants (n=187; 29.4% men and 70.6% women) were enrolled into this study 
(Figure 1). After collection of baseline measurements, 33 participants (17.6%) were excluded 
from further participation as a result of delayed ART initiation. By 12 months on ART, 53 
(28.3%) participants were lost to follow-up and this number increased to 95 (50.8%) 
participants at 24 months on ART. Patients were only classified as lost-to-follow-up when no 
further measurements were obtained from them. There was no difference in baseline 
characteristics between those lost to follow-up and those that remained in the study. Baseline 
characteristics are shown in Table 1. Men were significantly older than women (35 vs. 31 
years; p=0.008), and more men (71%) than women (56%) were initiated on a stavudine-based 
regimen. The proportion of participants on stavudine and tenofovir did not differ between 
commencement of ART and 12 months later. However, after 24 months on ART, the 
proportion of participants on a stavudine-based regimen had decreased and those on a 
tenofovir-based regimen had increased. More women were initiated onto nevirapine (69.8%) 
than efavirenz (30.2%). Only 1 participant was exposed to a drug regimen containing a 
protease inhibitor. Viral suppression (viral load <50 copies/mL) was achieved in 73% of 
participants after 6 months of ART. 
Change in anthropometric measures over the 24 month period is shown in Table 2 for women 
and Table 3 for men. In women, all anthropometric measures, except waist/hip ratio, showed 
a significantly increasing trend over time. In men, weight, BMI, mid-upper arm circumference, 
mid-thigh circumference, and skinfold thicknesses, showed a significantly increasing trend 





Figure 1. Consort diagram showing the number of participants lost to follow-up at each time 
point.  
 
*No further measurements were obtained from participants. 
 
Baseline 
N=187 (55 men & 132 women) 
 
33 excluded due to delayed 
ART initiation 
18 months on ART 
N=117 (32 men & 85 women)  
12 months on ART 
N=134 (38 men & 96 women)  
6 months on ART 
N=155 (45 men & 106 women) 
3 months on ART 
N=154 (46 men & 108 women) 
24 months on ART 
N=92 (26 men & 66 women)  
21 lost to 
follow-up* 
1 lost to 
follow-up* 
17 lost to 
follow-up* 
















Age 33.0 [27.0-39.0] 31.0 [26.0-38.0] 35.0 [29.0-41.0] 0.008 
CD4 156 [110-196] 161 [110-204] 137 [112-183] 0.126 
 n [%] n [%] n [%]  
Smoker 60 [32.3] 24 [18.3] 36 [65.5] <0.001 
Antiretroviral drugs     
NRTI     
Stavudine 110 [60.8] 71 [56.4] 39 [70.9] 0.065 
Zidovudine 20 [11.1] 19 [15.1] 1 [1.8] 0.009 
Tenofovir 51 [28.2] 36 [28.6] 15 [27.3] 0.858 
NNRTI           
Efavirenz 66 [36.5] 38 [30.2] 28 [50.9] 0.008 





Table 2. Comparison of anthropometric measures in women at baseline, 3, 6, 12, 18 and 24 months. 
























Height (m) 1.58 [1.55-1.62] 1.57 [1.54-1.62] 
 
1.58 [1.55-1.62] 1.58 [1.55-1.62] 1.57 [1.54-1.62] 1.58 [1.55-1.63] 0.340 
Weight (kg) 62.0 [54.8-71.3] 65.8 [57.5-73.6] 68.1 [58.2-77.0] 69.2 [59.3-82.8] 69.8 [59.8-81.8] 71.1 [57.6-84.4] <0.001 
BMI 24.8 [21.1-28.7] 26.3 [22.4-30.0] 27.1 [22.8-30.9] 27.8 [23.9-33.4] 28.3 [22.4-31.8] 27.7 [22.7-33.9] <0.001 
Sagittal abdominal 
diameter (cm) 
18.5 [16.5-21.0] 19.0 [16.5-21.5] 20.3 [16.5-22.3] 20.0 [17.6-22.6] 21.0 [18.0-23.8] 21.0 [18.0-24.8] <0.001 
Circumferences   
Waist (cm) 80.8 [74.5-90.5] 84.5 [76.0-93.0] 84.0 [76.0-93.5] 86.9 [79.0-96.8] 85.5 [79.0-97.0] 89.5 [76.0-100.5] <0.001 
Hip (cm) 98.0 [91.8-104.0] 100.5 [93.0-108.0] 104.0 [94.0-110.0] 105.0 [94.0-113.5] 104.5 [94.0-113.0] 105.0 [93.0-112.5] <0.001 
Waist/hip ratio 0.84 [0.79-0.92] 0.84 [0.80-0.89] 0.83 [0.77-0.88] 0.83 [0.80-0.89] 0.84 [0.79-0.88] 0.86 [0.81-0.91] 0.143 
Mid-upper arm (cm) 27.3 [24.0-27.0] 28.5 [25.5-31.5] 29.5 [26.0-32.5] 29.4 [26.0-33.0] 29.5 [25.8-33.0] 29.5 [25.5-33.5] <0.001 
Mid-thigh (cm) 55.0 [50.0-60.5] 56.0 [51.0-61.0] 59.0 [52.0-64.0] 59.0 [53.0-64.25] 59.0 [52.0-64.0] 60.0 [52.0-65.0] <0.001 
Skinfold thicknesses   
Biceps (mm) 7.0 [4.8-10.1] 7.4 [5.4-11.5] 8.4 [6.0-12.4] 8.7 [5.75-13.2] 8.6 [6.0-14.0] 9.0 [5.0-14.4] <0.001 
Triceps (mm) 17.2 [11.9-22.8] 19.2 [12.9-24.8] 21.4 [15.6-25.8] 22 [14.2-27.8] 21.2 [13.4-26.6] 21.1 [13.2-29.2] <0.001 
Abdomen (mm) 19.4 [13.9-31.4] 22.0 [15.8-32.0] 22.9 [17.0-34.0] 26.2 [18.65-38] 27.2 [19.0-37.0] 29.1 [19.1-39.8] <0.001 
Thigh (mm) 27.6 [20.4-36.0] 32.2 [23.2-39.0] 33.3 [23.2-41.4] 35.0 [24.1-44.2] 34.1 [25.0-42.3] 32.3 [22.0-41.2] <0.001 
Sub-Scapular (mm) 15.3 [10.0-24.4] 17.2 [11.3-27.3] 19.4 [11.9-29.2] 22.2 [12.6-32.0] 20.0 [13.0-30.3] 23.8 [13.6-31.0] <0.001 
Supra-iliac (mm) 11.1 [7.4-21.4] 13.4 [8.6-23.3] 15.5 [9.0-27.0] 18.5 [10.1-31.1] 17.6 [11.8-28.2] 21.2 [9.8-32.1] <0.001 




Table 3. Comparison of anthropometric measures in men at baseline, 3, 6, 12, 18 and 24 months.  


























Height (m) 1.7 [1.7-1.8] 1.7 [1.7-1.7] 1.7 [1.7-1.8] 1.7 [1.7-1.8] 1.7 [1.7-1.7] 1.7 [1.7-1.7] 0.475 
Weight (kg) 61.0 [55.0-67.0] 62.1 [55.8-68.2] 63 [56.2-69.0] 65.0 [60.6-72.0] 65.0 [60.0-74.0] 65.2 [59.0-70.5] 0.009 
BMI 21.3 [19.7-23.1] 21.2 [19.7-23.6] 21.4 [20.0-23.3] 22.0 [21.0-24.5] 21.9 [21.2-24.6] 21.8 [21.3-23.9] 0.003 
Sagittal abdominal 
diameter (cm) 
17.0 [15.8-18.5] 17.0 [15.5-18.0] 16.8 [15.0-18.0] 17.5 [16.3-20.0] 17.5 [16.5-19.5] 17.6 [16.3-19.0] 0.017 
Circumferences  
Waist (cm) 78.3 [74.0-83.0] 78.8 [76.0-83.0] 78.0 [75.0-83.5] 80.5 [75.0-86.5] 80.0 [76.0-86.0] 79.6 [75.0-83.5] 0.092 
Hip (cm) 88.4 [85.0-92.0] 88.0 [84.0-92.5] 90.0 [85.0-93.0] 90.0 [88.0-95.0] 91.0 [87.0-94.0] 89.0 [87.0-93.0] 0.071 
Waist/hip ratio 0.89 [0.86-0.92] 0.89 [0.86-0.92] 0.87 [0.85-0.92] 0.89 [0.85-0.93] 0.89 [0.85-0.93] 0.89 [0.84-0.93] 0.593 
Mid-upper arm (cm) 25.0 [24.0-27.0] 25.0 [24.0-27.0] 25.5 [24.0-27.0] 26.5 [25.0-28.5] 26.5 [25.0-28.0] 25.3 [24.5-27.0] 0.011 
Mid-thigh (cm) 48.0 [45.0-52.0] 48.0 [45.5-51.5] 48.5 [45.5-52.0] 50.0 [48.0-52.5] 50.0 [48.0-54.5] 48.0 [46.0-51.0] 0.017 
Skinfold thicknesses  
Biceps (mm) 3.2 [2.8-4.0] 3.4 [2.8-3.7] 3.3 [3.0-3.8] 3.4 [3.0-4.3] 3.8 [3.0-4.4] 3.7 [3.0-4.6] 0.030 
Triceps (mm) 5.8 [4.9-8.6] 6.3 [4.8-8.2] 6.0 [5.0-8.8] 7.0 [5.1-10.9] 7.0 [5.0-10.0] 6.8 [5.7-8.9] 0.035 
Abdomen (mm) 10.9 [7.8-15.6] 10.4 [8.6-14.4] 10.4 [7.7-17.8] 13.0 [8.4-20.4] 13.2 [8.4-19.4] 13.3 [9.3-18.5] 0.033 
Thigh (mm) 7.7 [5.7-12.0] 8.0 [6.0-13.5] 8.6 [6.0-12.4] 8.0 [5.9-12.4] 8.8 [6.3-11.6] 9.0 [6.8-10.0] 0.141 
Sub-Scapular (mm) 9.0 [6.5-9.7] 7.1 [6.4-9.3] 7.5 [6.6-10.2] 8.6 [6.6-11.4] 9.4 [7.2-12.3] 9.1 [6.8-11.9] 0.011 
Supra-iliac (mm) 5.8 [4.8-7.6] 6.0 [4.8-7.5] 6.0 [4.8-8.2] 6.4 [5.0-10.4] 7.2 [4.8-9.4] 6.7 [4.6-9.0] 0.084 




Cumulative measures for lipoatrophy and lipohypertrophy in men and women are shown in 
Table 4. Few self-reported cases of lipoatrophy or lipohypertrophy were recorded. The 
incidence of lipoatrophy, defined by limb fat loss as measured by DXA, increased in both men 
and women over the 24 month period. A greater proportion of men (9 of 42; 21.4%) than 
women (11 of 114; 9.6%) developed lipoatrophy by 24 months on ART when defined as ≥ 20% 
limb fat loss.  The proportion of participants who developed lipohypertrophy (defined as ≥ 
20% trunk fat gain) increased in both men and women by 24 months on ART. A similar 
proportion of men (25 of 42; 60%) and women (65 of 114; 57%) developed lipohypertrophy.   
Table 4. Cumulative number of participants with lipodystrophy assessed by patient report or DXA 




3 months 6 months 12 months 18 months 24 months 
Women        
Number at risk 114 101 94 83 75 
Lost to observation 14 10 7 10 15 
      
Lipoatrophy      
      Patient Report 1  1 1 1  1 
DXA ≥ 20% limb fat loss 1 1 6 8 11 
DXA ≥ 10% limb fat loss 6 7 15 19 26 
Lipohypertrophy      
      Patient Report 6 15 16 17 17 
DXA ≥ 20% trunk fat gain 17 31 53 63 65 
Men      
Number at risk 42 44 37 30 28 
Lost to observation 6 1 4 8 4 
      
Lipoatrophy      
      Patient Report 1  1  1 1 1 
DXA ≥ 20 % limb fat loss 2 3 5 8 9 
DXA ≥ 10 % limb fat loss 8 13 15 17 19 
Lipohypertrophy      
      Patient Report 1 3 3 3 3 




The highest ROC AUC of anthropometric measures for lipoatrophy were observed in women 
at 18 months on ART, and in men at 24 months on ART (Table 5). Anthropometric measures 
for lipohypertrophy performed poorly in women with no ROC AUCs ≥ 0.65 (Table 6). In men, 
three anthropometric measures for lipohypertrophy at 18 months generated ROC AUCs ≥ 
0.65 (sagittal abdominal diameter=0.732; waist circumference=0.661; waist/hip ratio=0.665) 
(Table 6). An illustration of ROC AUCs in descending order, for anthropometric measures 
associated with lipoatrophy (Figure 2) in women (A & B) and men (C & D), and for 
lipohypertrophy (Figure 3) in men, is shown. More anthropometric measures had a ROC AUC 
≥ 0.65 when lipoatrophy was defined as limb fat loss ≥ 20% than when it was defined as ≥ 
10%. Optimum cut-points for lipoatrophy variables with ROC AUCs of ≥ 0.65, based on 
likelihood ratios, were selected for men and women (Table 7). The thigh skinfold cut-point 
(≤24 mm) was able to correctly classify the greatest number of women (80.3%), both with 
lipoatrophy (sensitivity =62.5) and those without lipoatrophy (specificity=82.35). In men, the 
mid-arm circumference cut-point was able to correctly classify 69.6% of men, and was better 






Table 5. ROC AUC and 95% CI for anthropometric measures used to predict lipoatrophy 
defined as ≥20% limb fat loss in women and men at 12, 18 and 24 months on ART. ROC 




 12 months 18 months 24 months 
 ROC AUC [95%CI] ROC AUC [95%CI] ROC AUC [95%CI] 
Women n=87 n=76 n=65 
Waist/hip ratio 0.639 [0.534-0.744] 0.568 [0.447-0.679] 0.606 [0.471-0.720] 
Mid-thigh circumference 0.694 [0.581-0.785] 0.843 [0.740-0.916] 0.700 [0.566-0.801] 
Hip circumference 0.748 [0.643-0.834] 0.859 [0.756-0.925] 0.748 [0.631-0.852] 
Mid-arm circumference 0.695 [0.594-0.795] 0.740 [0.623-0.831] 0.616 [0.486-0.733] 
Biceps skinfold 0.711 [0.606-0.805] 0.605 [0.487-0.716] 0.625 [0.502-0.747] 
Triceps skinfold 0.714 [0.606-0.805] 0.764 [0.652-0.853] 0.660 [0.534-0.774] 
Calf skinfold 0.677 [0.569-0.774] 0.791 [0.681-0.875] 0.680 [0.559-0.798] 
Thigh skinfold 0.725 [0.618-0.815] 0.814 [0.710-0.895] 0.730 [0.598-0.827] 
Men  n=33 n=28 n=23 
Waist/hip ratio 0.560 [0.364-0.719] 0.614 [0.406-0.785] 0.667 [0.427-0.836] 
Mid-thigh circumference 0.565 [0.392-0.745] 0.621 [0.406-0.785] 0.672 [0.427-0.836] 
Hip circumference 0.637 [0.451-0.796] 0.504 [0.306-0.694] 0.650 [0.427-0.836] 
Mid-arm circumference 0.528 [0.335-0.692] 0.602 [0.406-0.785] 0.706 [0.471-0.868] 
Biceps skinfold 0.607 [0.421-0.771] 0.546 [0.339-0.725] 0.667 [0.427-0.836] 
Triceps skinfold 0.542 [0.364-0.719] 0.617 [0.406-0.785] 0.500 [0.306-0.732] 
Calf skinfold 0.597 [0.421-0.771] 0.519 [0.339-0.725] 0.506 [0.306-0.732] 




Table 6. ROC AUC and 95% CI of anthropometric measures used to predict 
lipohypertrophy defined as ≥20% trunk fat gain in women and men at 12, 18 and 24 
months on ART. ROC AUC values ≥0.65, which was our criterion for determining 
anthropometric cut-points, are in bold. 
  
 12 months 18 months 24 months 
 ROC AUC [95%CI] ROC AUC [95%CI] ROC AUC [95%CI] 
Women n=87 n=76 n=65 
Sagittal abdominal 
diameter 
0.518 [0.408-0.626] 0.559 [0.441-0.675] 0.540 [0.417-0.672] 
Waist circumference 0.507 [0.396-0.615] 0.580 [0.460-0.691] 0.550 [0.425-0.677] 
Hip circumference 0.543 [0.430-0.648] 0.594 [0.473-0.704] 0.592 [0.456-0.706] 
Waist/hip ratio 0.520 [0.408-0.626] 0.521 [0.408-0.642] 0.531 [0.410-0.663] 
Abdominal skinfold 0.519 [0.408-0.626] 0.577 [0.460-0.691] 0.502 [0.381-0.634] 
Sub-scapular skinfold 0.540 [0.430-0.648] 0.530 [0.408-0.642] 0.527 [0.395-0.649] 
Supra-iliac skinfold 0.526 [0.419-0.637] 0.606 [0.487-0.716] 0.510 [0.381-0.634] 
Men  n=33 n=28 n=23 
Sagittal abdominal 
diameter 
0.664 [0.482-0.820] 0.732 [0.537-0.889] 0.659 [0.427-0.836] 
Waist circumference 0.567 [0.392-0.745] 0.661 [0.476-0.841] 0.579 [0.345-0.768] 
Hip circumference 0.584 [0.392-0.745] 0.631 [0.441-0.814] 0.702 [0.471-0.868] 
Waist/hip ratio 0.592 [0.421-0.771] 0.655 [0.441-0.814] 0.501 [0.306-0.732] 
Abdominal skinfold 0.546 [0.364-0.719] 0.608 [0.406-0.785] 0.643 [0.427-0.836] 
Sub-scapular skinfold 0.523 [0.335-0.692] 0.576 [0.372-0.755] 0.532 [0.306-0.732] 




Figure 2. Lipoatrophy measures in women (A & B) at 18 months on ART and men (C & D) at 
24 months on ART with ROC AUCs and 95% confidence intervals in descending order of 
AUC. 
A – Women defined as ≥20% limb fat loss 
 
B – Women defined as ≥10% limb fat loss 
 
C – Men defined as ≥20% limb fat loss 
 
 




































Fig 3. Lipohypertrophy measures (defined as ≥20% trunk fat gain) in (A) women and (B) 
men at 18 months on ART with ROC AUCs and 95% confidence intervals in descending 
order of AUC.  
A – Women  
 
 
























Table 7. Anthropometric cut-points to identify lipoatrophy in women at 18 months on ART and men at 24 months on ART. Anthropometric 























Women (n=76)         
Hip circumference  ≤96 cm 75.00 73.53 2.83 0.34 25.00 73.53 73.68 
Mid-thigh circumference  ≤55 cm 87.50 70.59 2.98 0.18 25.93 70.59 72.37 
Mid-arm circumference ≤25 cm 23.53 93.22 3.47 0.82 50.00 93.22 77.63 
Thigh skinfold  ≤24 mm 62.50 82.35 3.54 0.46 29.41 82.35 80.26 
Triceps skinfold ≤16 mm 25.00 96.15 6.50 0.78 75.00 96.15 73.68 
Calf skinfold ≤16 mm 21.74 94.34 3.84 0.83 62.50 94.34 72.37 
Men (n=23) 
        
Mid-arm circumference ≤24 cm 20.00 83.33 1.20 0.96 25.00 83.33 69.57 
Mid-thigh circumference ≤48 cm 20.00 38.89 0.33 2.06 8.33 38.89 34.78 
Hip circumference ≤88 cm 10.00 69.23 0.33 1.30 20.00 69.23 43.48 
Waist/hip ratio ≤0.90 20.00 38.89 0.33 2.06 8.33 38.89 34.78 





This is the first study to develop simple diagnostic measures for lipodystrophy using 
longitudinal changes in DXA-derived measures of body fat composition as the reference 
standard. We found that simple anthropometric measures performed well for defining 
lipoatrophy in both men and women. The best predictors of lipoatrophy in women were hip 
and mid-thigh circumference, and thigh and calf skinfold thickness; and mid-arm 
circumference in men. The proportion of men and women who developed DXA-defined 
lipoatrophy increased over the 24 month period, but it occurred more frequently in men, 
possibly due to their lower baseline BMI as well as having less body fat, especially in the limbs. 
The proportion of men and women with DXA-defined lipohypertrophy increased until 18 
months on ART, before decreasing. The best predictor of lipohypertrophy in men was sagittal 
abdominal diameter, and no anthropometric measure was useful for predicting 
lipohypertrophy in women. We found very poor agreement between DXA-defined 
lipodystrophy and patient report, which grossly under-estimated lipodystrophy. 
Patient reports, using standardised questionnaires [6,20], are commonly used to assess 
lipodystrophy in low- and middle-income countries [25-27]. Results from studies comparing 
patient report to clinical examination have been contradictory [13-16]. One study reported a 
high level of agreement between patient and physician reported lipoatrophy and DXA-
measured limb fat [17]. We on the other hand, found very poor agreement between self-
report and DXA-defined lipodystrophy, with the proportion of participants with lipoatrophy 
and lipohypertrophy by self-report being far less than when defined by change in DXA 
measures in both men and women. These findings highlight the subjective nature of self-
report and suggest that the incidence of lipodystrophy in African studies may have been 
underestimated when the diagnosis was based solely on self-report.  
In low- and middle-income countries zidovudine continues to be used and stavudine was 
widely used until recently [28]. Lipoatrophy remains a common antiretroviral adverse drug 
reaction as both these drugs, especially stavudine, are associated with the development of 




independently associated with increased vascular risk [2-4]. Objective measures based on 
DXA-derived variables have been developed to define lipodystrophy in France [33], Portugal 
[34], and India [34,35]. These cross sectional studies, which consisted mainly of men, 
proposed that fat mass ratio (FMR), defined as the ratio of the percentage of the trunk fat 
mass to the percentage of the lower limb fat mass measured by DXA, be used for the early 
diagnosis of lipodystrophy [33-35]. These measures may not be generalizable to sub-Saharan 
Africa, where black South African women have less visceral adipose tissue than white South 
African women, despite being more insulin resistant and showing a different metabolic 
phenotype in sub-Saharan Africa [18]. Using an earlier cross sectional study consisting of 550 
participants on ART [11], our group developed objective measures for defining lipoatrophy 
and lipohypertrophy based on anthropometry and DXA-derived variables. We found the 
anthropometric variables triceps and thigh skinfold thickness to be the best predictors of 
lipoatrophy in women. However, all measures used patient report as the reference standard 
and may therefore be subject to the bias evident in self-report.  
To our knowledge no prior studies have used change from baseline in DXA-derived variables 
as the reference standard to define lipoatrophy and lipohypertrophy in order to develop cut-
points for anthropometric measures. We showed that several anthropometric measures 
could be used to diagnose lipoatrophy in women (hip, mid-thigh, and mid-arm 
circumferences; and thigh and calf skinfold), but mid-arm circumference was the only 
measure that had a ROC AUC of ≥ 0.65 in men.  Given that skinfold measurement requires 
equipment and training to ensure accuracy, we propose the use of hip, mid-thigh, and mid-
arm circumferences in women, and mid-arm circumference in men for defining lipoatrophy 
in African studies. Sagittal abdominal circumference was the only anthropometric measure 
that defined lipohypertrophy, and only achieved a ROC AUC of ≥ 0.65 in men. 
We showed that in both men and women, weight, waist circumference, sagittal abdominal 
diameter (a predictor of visceral fat [36]) and abdominal skinfold thickness increased 
significantly over time. After 18 months on ART more than half the women, and almost half 
the men had developed lipohypertrophy as defined by ≥ 20% increase in trunk fat. Even 




instead thought to be a consequence of treating the HIV infection [32], detecting increased 
trunk fat is clinically relevant as it has been shown to be associated with an increased risk of 
cardiovascular disease [2-4] and death in HIV-infected populations [37].   
There are some limitations to our study. There were no ART naive or HIV-uninfected control 
participants. The study sample was relatively small, with few participants being exposed to 
protease inhibitors, so only inferences about first-line ART can be made. Finally, rates of loss 
to follow up were high.  Despite these limitations, ours is the only study to use longitudinal 
changes from baseline in fat distribution measured by DXA to develop cut-points of simple 
anthropometric measures for diagnosing lipoatrophy and lipohypertrophy. 
7.6 Conclusion 
We developed anthropometric cut-points for defining lipodystrophy in South African HIV-
infected people on ART. These measures could be used in sub-Saharan Africa to identify 
lipoatrophy in both sexes and lipohypertrophy in men. Further research in other African 
countries is needed to validate these cut-points. 
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7.9 Supplementary Tables and Figures 
 Supplementary Table 1. Anthropometric cut-points to identify lipohypertrophy in men at 
18 months on ART. Anthropometric measures were selected for cut-point determination if 
their ROC AUC was ≥0.65. 
Supplementary Figure 1. ROC curves for anthropometric measures of lipoatrophy in women 
and men at 12, 18 and 24 months on ART. 
Supplementary Figure 2. ROC curves for anthropometric measures of lipohypertrophy in 
women and men at 12, 18 and 24 months on ART. 
Supplementary Figure 3. ROC curves for anthropometric measures of lipoatrophy in the 
combined sample of women and men at 12, 18 and 24 months on ART. 
Supplementary Figure 4. ROC curves for anthropometric measures of lipohypertrophy in 




Supplementary Table 1. Anthropometric cut-points to identify lipohypertrophy in men at 18 months on ART. Anthropometric measures were selected 






















Men (n=23)         
Sagittal abdominal diameter ≥18cm 73.91 75.00 2.96 0.35 94.0 33.0 17.11 
Waist circumference ≥80cm 80.00 46.15 1.49 0.43 63.0 67.0 12.22 




Supplementary Figure 1. ROC curves for anthropometric measures of lipoatrophy (defined as ≤20% limb fat loss) in women and men at 12, 18 and 
24 months on ART. 
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Supplementary Figure 2. ROC curves for anthropometric measures of lipohypertrophy (defined as ≤20% trunk fat gain) in women and men at 12, 18 
and 24 months on ART. 
 Women  Men  
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Supplementary Figure 3. ROC curves for anthropometric measures of lipoatrophy (defined as 
≤20% limb fat loss) in the combined sample of women and men at 12, 18 and 24 months on ART. 
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Supplementary Figure 4. ROC curves for anthropometric measures of lipohypertrophy (defined 
as ≤ 20% trunk fat gain) in the combined sample of women and men at 12, 18 and 24 months on 
ART. 
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Chapter 8. Summary and Recommendations 
This chapter presents a summary of the key findings in relation to the thesis aims and 
objectives, and its implications and recommendations for clinical practice, policy change and 
future research  
8.1 Thesis aim and methods 
This thesis investigated specific metabolic complications associated with the use of ART 
(hypertension, dysglycaemia and lipodystrophy), and thereafter developed simple 
anthropometric cut-points to assist in identifying those with lipodystrophy. Data for this 
thesis came from three datasets (one cross sectional and two longitudinal studies), collected 
between 2007 and 2013 of black HIV-infected men and women presenting to ART clinics in 
Cape Town.  
To investigate the metabolic complications associated with the use of ART, a longitudinal 
dataset consisting of 103 women who had spent a median of 6.8 years on ART, was used. The 
complications assessed were: hypertension, defined as BP ≥140/90 mmHg or using 
antihypertensive agents; dysglycaemia using an oral glucose tolerance test (OGTT); insulin 
resistance estimated by HOMA-IR; β-cell function using the insulinogenic index (IGI) and the 
oral disposition index (DIo); lipoatrophy defined as ≥ 20% loss of limb fat from baseline; and 
lipohypertrophy defined as ≥ 20% gain in trunk fat from baseline by DXA scan. Data were 
analysed using descriptive statistics which included non-parametric t-tests and McNemar chi-
square t-tests for paired data. The second longitudinal dataset, consisting of 55 men and 132 
women who were ART-naïve at baseline, was used to describe the changes in fat distribution 
over a 24 month period. Data analysis included (1) the Jonckheere-Terpstra test for ordered 
variables which was used to measure trends over time, (2) the Kaplan-Meier estimator which 
was used to assess differences in time to lipoatrophy and lipohypertrophy in men and women, 
(3) the Cox proportional hazards regression model and logistic regression model which was 




lipoatrophy and lipohypertrophy, and (5) latent class mixed effects models which were used 
to estimate the mean longitudinal trajectories in potentially heterogeneous populations. 
The cross sectional dataset, consisting of 116 men and 434 women on ART, was used to 
develop simple measures for defining lipoatrophy and lipohypertrophy using patient report 
as the reference standard. Data analysis consisted of descriptive statistics and receiver 
operating characteristic (ROC) curves, which were used to describe the performance of a 
number of anthropometric and DXA-derived variables. As patient report is a subjective 
method of assessment, a longitudinal dataset consisting of 187 participants, was used to 
validate the measures that were developed, this time using change in DXA measures as the 
reference standard.  Data analysis consisted of descriptive statistics, the Jonckheere-Terpstra 
test for ordered variables which was used to measure trends over time, and ROC curves which 
were used to describe the performance of a number of anthropometric variables using 
change in DXA measures as the reference standard. 
8.2 Summary findings 
In summary, antiretroviral therapy was significantly associated with the development of 
metabolic complications, and anthropometric cut-points were developed that successfully 
predicted lipodystrophy.  
The key findings are as follows: 
1. There were significant changes in both systolic and diastolic blood pressure over time 
2. Plasma glucose and insulin concentrations, as well as markers of insulin sensitivity and 
β-cell function changed significantly during the five year follow-up period 
3. Change in body fat distribution following ART initiation occurred differently in men 
and women 
4. When using patient report as the reference standard, the best predictors of 
lipoatrophy in women were triceps and thigh skinfold thickness, while lipohypertrophy 




5. When using change in DXA measures as the reference standard, thigh skinfold and 
mid-arm circumference correctly classified the greatest number of women with 
lipoatrophy, and mid-arm circumference correctly classified the greatest number of 
men with lipoatrophy 
6. There was poor agreement between patient-reported lipodystrophy and DXA-derived 
lipodystrophy 
Details and an in-depth discussion of these key findings can be found in the 3 published and 
1 unpublished paper (Chapter 4-7). These findings and their interpretations are summarised 
as follows: 
8.2.1 ART is associated with an increase in blood pressure levels 
Median systolic and diastolic blood pressure increased significantly (p<0.001) during the five 
year follow-up period. While only 4% of participants had hypertension at baseline, the 
proportion significantly (p<0.001) increased to 15.5% after 5.5 years. The antiretroviral drugs 
stavudine, efavirenz and nevirapine were significantly (p<0.001) associated with the 
development of hypertension. These findings could be used to inform clinical practice in 
public health facilities, where efavirenz and nevirapine are still being used as part of the first-
line ART treatment regimen. 
8.2.2 ART is associated with an increase in diabetes 
Plasma glucose concentrations showed a significant increase from baseline to follow-up at 
both 30 minutes (p=0.040) and 120 minutes (p=0.028), while plasma insulin concentration 
showed significant increases at 0 minutes (p=0.009) and 30 minutes (p<0.001). HOMA-IR 
increased from baseline to follow-up, indicating a decrease in insulin sensitivity. In addition, 
both IGI and DIo increased significantly (p<0.001), indicating a rise in insulin secretion in 
relation to insulin resistance. While the proportion of participants with dysglycaemia did not 
change from baseline to follow-up, the proportion of participants with diabetes increased (1% 
to 7.5%), as did the proportion of participants with impaired glucose tolerance (5.8% to 9.6%). 
The development of diabetes and dysglycaemia were significantly associated with the 




the development of insulin resistance and diabetes in large studies from high-income 
countries [1,2] as well as a recent study from South Africa [3], and has only recently been 
phased out in South Africa, and efavirenz and nevirapine continue to be used as part of the 
first-line ART treatment regimen, these findings should be used as motivation for regular 
monitoring of glucose levels in patients on first-line ART treatment in South Africa.    
8.2.3 ART is associated with changes in body fat distribution  
Women who were on ART for a median of 16 months at baseline, experienced no change in 
weight or BMI during the 5.5 year follow-up period. However they had significant changes in 
fat distribution; with increases in abdominal, sub-scapular and supra-iliac skinfold thickness 
(p<0.001), as well as waist (p=0.038), hip (p<0.001) and mid-thigh (p<0.001) circumference. 
In addition, they experienced a significant decrease in their biceps (p=0.011), triceps 
(p=0.007), thigh and calf skinfold (p<0.001) thickness. However, when using a longitudinal 
study of men and women who were ART-naïve at baseline, both men and women experienced 
significant increases in weight (p<0.009) and BMI (p<0.002) following ART initiation. Women, 
experienced a significant increasing trend in trunk fat and a significant decreasing trend in 
limb fat, when expressed as a percentage of total body fat. These changes suggest 
centralisation of body fat, in addition to peripheral wasting, and is in agreement with 
numerous studies from sub-Saharan Africa [4-6]. In addition, these findings indicate that 
following ART initiation, patients experience a return to health as evidenced by an increase in 
weight and BMI. However, after several months on ART, weight and BMI stabilise, while limb 
fat continues to decrease and trunk fat continues to increase, thus indicating the continued 
development of lipoatrophy and lipohypertrophy.  These findings highlight the need for a 
simple, inexpensive tool that can be used to assess lipoatrophy and lipohypertrophy in men 
and women. 
8.2.4 Changes in body fat distribution occurs differently in men and women on 
ART 
Women, compared to men gained significantly more overall weight (9kg vs. 4kg) and more 
regional fat in all areas analysed on DXA scans. Cox proportional hazards regression modelling 




lipoatrophy. Men had a 2.9 times greater risk of developing lipoatrophy compared to women, 
after adjusting for age, baseline BMI and ART regimen. Women, but not men, experienced a 
significant decrease in limb fat when expressed as a percentage of total body fat (p<0.001 vs. 
p=0.248), and a significant increase in trunk fat percentage (p<0.001 vs. p=0.085). However, 
the incidence of lipoatrophy when expressed as a categorical variable was higher in men than 
women (20% vs. 9.4%; p=0.066), while the incidence of lipohypertrophy, when expressed as 
a categorical variable, occurred similarly in men (60%) and women (57%). Further 
investigation is required to understand the mechanisms underlying the sex differences in 
changes in body fat distribution and its effects on cardiovascular risk. 
8.2.5 Development of objective measures to define lipoatrophy and 
lipohypertrophy  
Using patient report as the reference standard, triceps and thigh skinfold thickness correctly 
identified the greatest percentage of women with lipoatrophy (68.7% and 65.7%, 
respectively), while waist/hip ratio correctly identified the greatest percentage with 
lipohypertrophy (64.8%). When using change in DXA measures as the reference standard, 
thigh skinfold thickness and mid-arm circumference correctly identified the greatest 
percentage of women with lipoatrophy (80.3% and 77.6%, respectively), and mid-arm 
circumference correctly identified the greatest percentage of men (69.6%) with lipoatrophy. 
These finding prove that simple measures of anthropometry can successfully be used to 
diagnose lipoatrophy and lipohypertrophy in men and women in South Africa. 
8.2.6 Poor agreement between patient-reported lipodystrophy and DXA-defined 
lipodystrophy 
The incidence of lipodystrophy by patient report was far lower than when defined by DXA 
measures. Based on patient report, only one man and one women developed lipoatrophy. 
However, when using change in DXA measures (defined as ≥ 20% limb fat loss), 11 women 
and 9 men were diagnosed with lipoatrophy. Similarly, fewer men and women (17 and 3, 
respectively) reported having lipohypertrophy compared to when lipohypertrophy was 
diagnosed using change in DXA measures (defined as ≥ 20% trunk fat gain) as the reference 




and suggest that the incidence of lipodystrophy may be underestimated when the diagnosis 
is based solely on self-report. 
8.3 New information (or contributions) from this thesis 
Based on the summary findings of this thesis, the following new information emerged: 
 Antiretroviral therapy may be associated with an increased risk of diabetes and 
hypertension in black South Africans 
 Black men are at a greater risk of developing lipoatrophy when compared to black 
women 
 There is poor agreement between patient reported lipodystrophy and DXA-defined 
lipodystrophy 
 This is the first study in Africa to develop tools to define lipoatrophy and 
lipohypertrophy 
 Anthropometric variables can be used to diagnose ART-related lipoatrophy and 
lipohypertrophy in South African men and women 
8.4 Implications for clinical practice and policy change 
The findings of this thesis showed that long-term use of ART results in an increase in both 
systolic and diastolic blood pressure, as well as an increase in the prevalence of hypertension 
and possibly diabetes. Furthermore, the findings showed that hypertension, dysglycaemia 
and diabetes were associated with the drugs stavudine, efavirenz and nevirapine, and 
diabetes was additionally associated with the drug zidovudine.  During the coming years, the 
number of ART users are predicted to increase in low- and middle-income countries as they 
expand their ART programmes in following the World Health Organisation’s recommendation 
to ‘test and treat’ [7] by initiating all HIV-infected patients, irrespective of CD4 count.  




continues to be used in South Africa as part of their first-line ART treatment regimen [8], the 
incidence of antiretroviral-associated hypertension and diabetes may also increase. Even 
small increases in the prevalence of hypertension and diabetes may result in considerable 
public health impact on the prevalence of cardiovascular disease. These findings could be 
used to inform clinical practice in public health facilitiessuch asregular monitoring of blood 
pressure and blood sugar levels in patients on ART. 
This thesis showed that more than 20% of men developed lipoatrophy; that the risk of 
development was far greater in men compared to women; and that the time to development 
did not differ by gender. On the other hand, lipohypertrophy occurred in more than half the 
participants, and occurred similarly in men and women. Both men and women, to varying 
degrees, experienced an increase in central fat and a decrease in subcutaneous fat, indicative 
of lipoatrophy and lipohypertrophy. The development of lipodystrophy is associated with an 
increase in cardiometabolic risk factors such as dyslipidaemia and dysglycaemia. Patients with 
lipodystrophy may develop impaired glucose tolerance and insulin resistance, as well as 
increased levels of triglycerides and decreased levels of HDL cholesterol. These findings have 
important implications for the management of HIV in Africa, as the early identification and 
management of these cardio-metabolic risks are crucial in the region with the highest HIV-
infected population in the world. 
This is the first study in Africa to develop tools to identify lipoatrophy and lipohypertrophy. 
This thesis showed that a number of anthropometric variables can be used to diagnose 
lipoatrophy and lipohypertrophy with varying degrees of accuracy. Those developed using 
change in DXA measures (i.e. hip, mid-thigh and mid-arm circumference) are likely to be more 
accurate than the measures developed using patient report as the reference standard (i.e. 
triceps and thigh skinfold thickness), due to the subjectivity of patient report. While training 
and well maintained skinfold callipers are necessary to accurately identify patients with 
lipoatrophy using triceps and thigh skinfold thickness, the circumferences are easily and 
quickly measured, and require minimal training and only an inexpensive tape measure. These 




health professionals are overburdened and need simple, inexpensive and quick methods for 
diagnosing patients. 
This thesis showed very poor agreement between self-report and DXA-defined lipodystrophy, 
with the proportion of participants with lipoatrophy and lipohypertrophy by self-report being 
far less than when defined by change in DXA measures in both men and women. Currently in 
South Africa, lipoatrophy and lipohypertrophy are diagnosed by patient report, and 
occasionally by a healthcare professional. These findings highlight the subjective nature of 
self-report and suggest that the incidence of lipodystrophy in African studies may have been 
underestimated when the diagnosis was based solely on self-report.  
8.5 Clinical practice and policy recommendations  
This section outlines recommendations for clinical practice and policy, based on the findings 
of the thesis. The overarching recommendation is to regularly monitor patients taking 
antiretrovirals, to ensure the early identification and treatment of the metabolic 
complications of ART. 
1. Regular monitoring of blood pressure and glucose levels will be required to identify 
hypertensive and diabetic patients as early as possible. However, these 
recommendations are of particular concern in South Africa where healthcare facilities, 
based on national guidelines and in an attempt to decongest healthcare facilities [9], 
are now offering stable ART patients the option of collecting their medication from 
external service providers for a period of 6 months before returning to the healthcare 
facility for renewal of the prescription. These national guidelines only allow for annual 
assessment of patients. Hence, by following these guidelines, patients who develop 
elevated blood pressure or glucose levels as a result of their medication, risk going 
undetected for many months. To ensure the early identification and treatment of 
these metabolic complications, regular monitoring of blood pressure and glucose 
levels in patients on ART is recommended. While blood pressure is easy to monitor, 




alone may miss patients with diabetes who have an abnormal 120 minute OGTT. 
However, an OGTT is cumbersome and takes 120 minutes to complete. An HbA1c test, 
while using a non-fasting blood sample, requires a laboratory test. In addition, the 
diagnostic cut-points used may not be applicable to patients on ART.  
2. The findings of this thesis showed that patient-reported lipodystrophy had a tendency 
to underestimate the true incidence of lipoatrophy and lipohypertrophy. As 
lipodystrophy is subjectively measured by patient report in South Africa, and both 
lipoatrophy and lipohypertrophy are frequently found in patients on ART, objective 
tools for identifying those with lipoatrophy and lipohypertrophy are needed. 
Operational Managers at healthcare facilities in South Africa need to ensure that all 
ART patients undergo a clinical examination using objective measures to diagnose 
lipodystrophy before new prescriptions are dispensed.  
3. In addition to regular monitoring of blood pressure and glucose levels, body fat 
changes in ART patients need to be identified. This will require the use of simple, 
inexpensive tools that require minimal training, and can be performed by an enrolled 
nurse, but can accurately diagnose both lipoatrophy and lipohypertrophy in men and 
women. The anthropometric cut-points developed in this thesis meets these 
requirements. The enrolled nurse in charge of the vitals station at healthcare facilities 
should be trained to measure circumferences of ART patients in addition to the normal 
weight and height measurements. This will help track changes in weight and BMI as 
well as limb fat loss and trunk fat gain. 
4. After 24 months on ART, more than half the men and women enrolled in the study 
had developed lipohypertrophy. As central fat gain is a known cardiometabolic risk 
factor, patients who develop an enlarged waist circumference are potentially at risk 
of developing dyslipidaemia and dysglycaemia. It is thus essential to monitor glucose 
and cholesterol levels regularly. These measurement should be incorporated into the 
annual assessment patients attending public healthcare facilities need to undergo. In 




preventable risk factors that may impact their cardiovascular risk such as smoking 
cessation and dietary management to help decrease their risk of developing 
cardiovascular disease. 
5. Before ART initiation, a large number of woman were either overweight or obese. 
After 24 months on ART, the proportion of overweight or obese women had increased 
substantially. Studies on weight perception in HIV-infected women reported a 
mismatch between actual weight and weight perception [10,11], with a tendency for 
women to judge themselves as less than their actual weight. In South Africa, HIV-
infected women continue to experience discrimination, which may be the cause of 
intentional obesity as a mechanism of limiting the stigma [12]. While high levels of 
obesity have been reported in uninfected women as well, it is still of concern. These 
patients may benefit from regular weight assessments and counselling on the 
importance of exercise and a healthy diet when their weight increases. Adherence 
clubs could act as a platform for group counselling sessions so that individuals do not 
feel targeted. 
8.6 Recommendations for future research 
1. Further research using large prospective cohorts with adequate numbers on modern 
drug regimens as well as an HIV-naïve and an uninfected control is needed to confirm 
the increased risk of diabetes and hypertension found in this study; to identify specific 
drug interactions; and to confirm the greater risk of lipoatrophy in men compared to 
women. 
2. Additional research is also required to understand the mechanisms underlying the sex 
differences in changes in body fat distribution and its effects on cardiovascular risk 
3. As this is the first study in Africa to develop tools to define lipoatrophy and 
lipohypertrophy, these measures need to be validated in other cohorts in Africa using 




8.7 Strengths and limitations of the studies 
The study findings need to be interpreted within the context of its strengths and limitations. 
The cross sectional study design (Chapter 6), while allowing us to make associations, did not 
allow us to infer causality. With changes in fat distribution, repeated objective measures 
would have given us a better reference standard than patient report, even though patient 
report is commonly used. We did not have enough men with lipoatrophy or lipohypertrophy, 
to explore predictive anthropometric and DXA-derived variables.  Finally, the likelihood ratios 
for the most predictive anthropometric and DXA-derived variables were only weakly 
diagnostic of self-report lipoatrophy and lipohypertrophy. In spite of these limitations, the 
sample size was relatively large, and unlike most studies from Africa, we used DXA 
measurements as well as anthropometry and patient self-report to define lipoatrophy and 
lipohypertrophy.  
The lack of HIV-uninfected and ART-naïve control groups in Longitudinal Study A (Chapter 4) 
limited our ability to attribute the changes observed to the use of ART. The sample consisted 
exclusively of women, which prevented us from investigating whether hypertension, 
glycaemia and fat redistribution developed differently by gender. The sample size was also 
relatively small, which limited our ability to assess whether the increased prevalence of 
diabetes over time was significant. Despite its many limitations, this study has a few strengths. 
This is one of very few studies in Africa to follow women on ART for over 5 years, and to use 
an OGTT to define dysglycaemia.     
Longitudinal study B (Chapter 5 and 7) was a non-randomised study, and there were no 
untreated or uninfected controls for comparison. Few participants were exposed to protease 
inhibitors, so only inferences about first-line ART could be made. The study sample was 
relatively small, with a high rate of loss to follow-up, resulting in a lack of power. Regardless 
of these limitations, this is the only study from Africa to use longitudinal data, and to collect 
DXA measurements at six time points during the 24 month period. The sample consisted of 
both men and women, which allowed us to assess how fat redistribution differed by gender. 




measured by DXA to develop cut-points of simple anthropometric measures for diagnosing 
lipoatrophy and lipohypertrophy. 
As stavudine has already been discontinued in South Africa and the number of patients on 
zidovudine are minimal and may be replaced by a less toxic drug in the near future, the 
findings of this thesis are unfortunately not as important as they would have been 10 years 
ago. As the metabolic complications observed in this thesis were primarily related to the use 
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